Deficiency of Krüppel-like factor 15 activates β-catenin and is involved in the development of osteoarthritis

Deficiency of Krüppel-like factor 15 activates β-catenin and is involved in the development of osteoarthritis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Deficiency of Krüppel-like factor 15 activates β-catenin and is involved in the development of osteoarthritis Akira Saitoh, Shinya Hayashi, Toshiki Kitamura, Takuma Hayashi, and 14 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8429330/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 9 You are reading this latest preprint version Abstract Krüppel-like factor 15 is a metabolism-related transcription factor that has been implicated in the regulation of the Wnt/β-catenin signaling pathway. This study aimed to elucidate its function in cartilage, particularly its interaction with β-catenin, using inducible cartilage-specific knockout mice. Krüppel-like factor 15 knockout mice and control mice underwent destabilization of medial meniscal surgery to induce osteoarthritis. Histological analysis and immunohistochemistry were carried out, along with in vitro co-immunoprecipitation, double immunofluorescence, and subcellular fractionation. The effects of Wnt3A stimulation and treatment with Wnt/β-catenin inhibitors were evaluated. KO mice showed significantly more cartilage degeneration at eight weeks after surgery when compared with control mice. Knockout mice also showed elevated Osteoarthritis Research Society International scores and increased expression of β-catenin, matrix metalloprotease 13, and a disintegrin-like metalloprotease with thrombospondin motifs 5, along with decreased expression of SRY-box transcription factor 9. Krüppel-like factor 15 was seen to physically interact and colocalize with β-catenin in chondrocyte nuclei. Its deficiency promoted Wnt/β-catenin pathway activation and nuclear β-catenin accumulation. Wnt3A stimulation amplified catabolic gene expression and suppressed anabolic factor expression. However, administration of a Wnt/β-catenin signaling inhibitor canceled out these effects. This study indicates that Krüppel-like factor 15 interacts with β-catenin and functions as a negative regulator of Wnt/β-catenin signaling in cartilage, maintaining matrix homeostasis, and suppressing osteoarthritis progression. Deficiency of Krüppel-like factor 15 promotes catabolism and inhibits anabolism mediated by β-catenin in cartilage. These findings suggest that Krüppel-like factor 15 may be a potential therapeutic target for osteoarthritis, either by restoring its function or enhancing its interaction with β-catenin. Krüppel-like factor 15 Wnt/β-catenin pathway β-catenin osteoarthritis destabilization of medial meniscal surgery Wnt3A matrix metalloprotease 13 disintegrin-like metalloprotease with thrombospondin motifs 5 SRY-box transcription factor 9 Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Background Osteoarthritis (OA) is a common joint disease that develops due to aging and lifestyle habits, which significantly reduces quality of life. 1 , 2 The pathology of OA progresses as a series of complex changes in the entire joint structure, accompanied by degeneration of articular cartilage, synovitis, bone sclerosis, and osteophyte formation. To date, no effective disease-modifying treatment has been established to treat OA. 3.4 Artificial joint replacement surgery has delivered good long-term results. 5 However, the efficacy of conservative treatments such as analgesics, hyaluronic acid injections, and rehabilitation is limited in their efficacy. 6 Therefore, elucidating the mechanisms underlying OA progression and identifying new therapeutic targets is necessary. Krüppel-like factors (KLFs) are a family of transcription factors with C2H2-type zinc fingers that are involved in a wide range of biological processes. 7 Currently, 17 members of the KLF family have been identified, each with different tissue specificities and functions. 8 , 9 Recently, the involvement of KLFs in OA has attracted attention. In particular, KLF2 and KLF4, which are involved in the maintenance of chondrocyte homeostasis, are known to be associated with OA pathology. 10 KLF2 inhibits oxidative stress and ferroptosis and protects mitochondrial function in chondrocytes, thereby suppressing OA progression. Specifically, KLF2 inhibits the oxidative stress response by activating Nrf2/ARE signaling. 11 It improves ferroptosis and mitochondrial dysfunction via the SIRT1/GPX4 pathway, thereby alleviating OA pathology. 12 KLF4 promotes chondrocyte differentiation and expression of extracellular matrix (ECM) components, and is considered an important transcription factor in cartilage repair regulation. Furthermore, KLF4 has a protective function in OA by regulating the inflammatory response of synovial cells and chondrocytes and suppressing tissue destruction. 13 , 14 KLF15 is a metabolism-related transcription factor that functions as a key regulator of metabolic homeostasis in various tissues, specifically in lipid metabolism and energy homeostasis. 15 – 18 In skeletal muscle, KLF15 cooperates with peroxisome proliferator-activated receptor delta (PPARδ) to regulate lipid flux and maintain mitochondrial function, contributing to exercise response and muscle function adaptation. 19 However, the possibility that KLF15 may also be involved in the pathology of OA has recently attracted attention. Disruption of lipid metabolism is considered a new pathological factor involved in the disturbance of cartilage homeostasis and OA progression. 20 Abnormal fatty acid oxidation impairs cartilage homeostasis through SRY-box transcription factor 9 (SOX9) degradation and epigenetic regulation. 21 Such metabolic abnormalities promote cartilage degeneration. Therefore, KLF15 may function as a metabolic regulator even within chondrocytes. KLF15 directly induces SOX9 expression during chondrogenic differentiation of human mesenchymal stem cells (hMSCs) and promotes cartilage differentiation. 22 Additionally, KLF15 expression is significantly reduced in chondrocytes derived from patients with OA compared with healthy individuals. 10 Furthermore, KLF15 plays a role in suppressing the inflammatory response and progression of matrix degradation by suppressing matrix metalloproteinase-13 (MMP-13) transcription in response to tumor necrosis factor-alpha (TNFα) stimulation. 23 Our previous study reported that KLF15 deficiency reduces peroxisome proliferator-activated receptor gamma (PPARγ) expression, which promotes chondrocyte apoptosis, resulting in the worsening of OA pathology. 24 Thus, KLF15 is a multifaceted transcription factor that contributes to the metabolic regulation, differentiation control, and suppression of inflammatory responses in cartilage. Specifically, its role in homeostasis is extremely important. However, the role of KLF15 in cartilage homeostasis and the progression of OA pathology has not yet been fully elucidated, and further research is required. The Wnt/β-catenin signaling pathway is a highly conserved and fundamental signaling cascade that plays pivotal roles in several biological processes. 25 Canonical Wnt signaling through β-catenin is activated by Wnt ligand binding to the cell surface Frizzled receptor and co-receptor low-density lipoprotein receptor-related protein (LRP) 5/6. In the absence of Wnt ligands, cytoplasmic β-catenin is targeted for proteasomal degradation via a degradation complex, which phosphorylates β-catenin and marks it for ubiquitination. Upon Wnt activation, this degradation machinery is inactivated and β-catenin accumulates in the cytoplasm before translocating to the nucleus. There, Wnt/β-catenin activates the transcription of various target genes involved in cell proliferation, differentiation, and matrix remodeling. 26 The Wnt/β-catenin pathway is essential for proper cartilage tissue development and maintenance under physiological conditions. Its dysregulation has been suggested to be deeply involved in OA pathology. Evidence suggests that abnormal or persistent activation of this pathway promotes the expression of degradative enzymes, such as MMP13 and disintegrin-like metalloprotease with thrombospondin motifs 5 (ADAMTS5), which are central mediators of ECM degradation in OA cartilage. 27 – 29 These enzymes degrade collagen type II alpha 1 (Col2A1) and aggrecan, resulting in the structural destruction of articular cartilage. In particular, overexpression of β-catenin has been reported to be involved in the progression of OA. 30,31 Interestingly, recent studies suggest that transcription factors, such as KLF15, which regulate metabolic and signaling pathways in other tissues, such as the heart and kidney, may interact with Wnt/β-catenin signaling. 17 , 32 These findings suggest that KLF15 may also affect cartilage integrity by regulating the expression of β-catenin in chondrocytes. Information regarding the crosstalk between KLF15 and β-catenin in OA pathology is currently scarce. Understanding the precise nature of the involvement of KLF15 in the Wnt/β-catenin pathway may help to identify novel transcriptional regulatory mechanisms in OA and aid in identifying future therapeutic targets. In this study, we aimed to evaluate how the interaction between KLF15 and β-catenin regulates OA progression using a KLF15-deficient mouse model. Materials and methods Generation of inducible cartilage-specific KLF15 knockout mice Mice were maintained under a 12-h light/dark cycle with free access to food and water. Klf15 fl/fl mice were generated as described previously. 33 Col2-CreERT2 mice were obtained from Jackson Laboratories (Bar Harbor, Maine, USA). Klf15 fl/fl mice were crossed with Col2-CreERT2 mice to generate inducible KLF15 knockout mice (Klf15 fl/fl Cre mice). Genotyping was performed on tail biopsy samples by polymerase chain reaction (PCR) using a DNA extraction kit (Qiagen, Valencia, California, USA). Klf15 fl/fl littermates negative for Col2-CreERT2 were used as wild-type controls. To induce gene deletion, 6-week-old Klf15 fl/fl Cre mice and control mice were intraperitoneally injected with 4-hydroxytamoxifen (40 mg/kg) for 5 consecutive days. In this study, only male mice were used because they develop more severe OA than females. 34 All mice were backcrossed to the C57BL/6 background for more than six generations. Each experimental group included at least six mice. In vivo OA mouse model All animal procedures were conducted in strict accordance with the National Institutes of Health guidelines for the care and use of laboratory animals (Bethesda, MD, USA). The Animal Research Committee of Kobe University approved the protocol (approval number: P230606). Ten-week-old male Klf15 fl/fl Cre and control mice were used. All surgical procedures were performed on the right knee joint under combined anesthesia (medetomidine, 0.375 mg/kg; midazolam, 2.0 mg/kg; butorphanol, 2.5 mg/kg). OA was induced by destabilization of the medial meniscus (DMM) via medial meniscotibial ligament. 35 Sham operations involved exposure without ligament transection. Mice were allowed to bear weight after recovery. Mice were euthanized for histological evaluation at 1 day, 1 week, 4 weeks, and 8 weeks post-operation or at 8 weeks post-sham. Six mice were analyzed per group (total n = 60; KLF15 KO Sham, KLF15 KO DMM, Control Sham, Control DMM). Histological evaluation of cartilage degeneration Knee joints were fixed in 10% neutral-buffered formalin for 24 h, decalcified with 4% ethylenediaminetetraacetic acid for 7 days, and embedded in paraffin. Coronal sections were cut at 80 µm intervals and stained with Safranin O and Fast Green. OA severity was evaluated using the Osteoarthritis Research Society International (OARSI) cartilage histopathology scoring system. Immunohistochemistry Deparaffinized sections were digested for 10 min with proteinase (Dako, Glostrup, Denmark) and treated with 3% hydrogen peroxide (Wako Pure Chemical Industries, Osaka, Japan) to block endogenous peroxidase activity. Sections were incubated overnight at 4°C with the following primary antibodies: anti-β-catenin (1:5000, bs-0530R, Abcam, Cambridge, UK), anti-ADAMTS5 (1:50, GTX100332, GeneTex, Irvine, CA, USA), anti-MMP13 (1:50, GTX100665, GeneTex), and anti-SOX9 (1:200, ab185230, Abcam, Cambridge, UK). Secondary antibody incubation was performed using peroxidase-labeled antirabbit immunoglobulin (Histofine Simple Stain MAX PO; Nichirei Biosciences, Tokyo, Japan) at 22 ± 2℃ for 30 min, followed by staining with 3,3'-diaminobenzidine (DAB; Histofine Simple Stain DAB kit; Nichirei Biosciences, Tokyo, Japan). One coronal section at the center of the most severe OA lesion of each tibial plateau was analyzed. The number of positively stained cells in both superficial and deep zones of cartilage was counted in three high-power fields by three blinded observers. The mean percentage of positive cells to total cells was calculated for each marker per group (n = 6). Cells above the tidemark were considered positive. Isolation of mouse cartilage and chondrocytes Cartilage tissues were isolated from fetal rib cages. Klf15 fl/fl Cre mice were mated, and pregnant female mice were intraperitoneally injected with tamoxifen at 12.5 and 13.5 days post coitum (dpc). Fetuses were harvested from these mice by Caesarean section at 18.5 dpc. Genotyping was performed on tail biopsy samples by PCR using a DNA extraction kit (Qiagen, Valencia, California, USA). Primary chondrocytes were isolated from cartilage by digestion with 3 mg/mL collagenase D (Roche, Basel, Switzerland) in Dulbecco’s Modified Eagle’s Medium (DMEM; D5546, Sigma-Aldrich, St. Louis, MO, USA) at 37℃ under 5% CO₂ for 45 min. The digestion was repeated after transferring the cartilage pieces to a new dish. The resulting cells were cultured overnight in a 1:5 mix of culture medium (DMEM supplemented with 2 mM glutamine, 50 U/mL penicillin, 0.05 mg/mL streptomycin) and digestion solution. Non-adherent cells were removed, and adherent cells were further cultured with 10% fetal bovine serum (FBS; 50 mL per 500 mL DMEM) for 5–6 days until confluence. First-passage cells were used in all experiments. Co-immunoprecipitation Primary cultured chondrocytes from control fetal costal cartilage were used. Cells were lysed in M-PER cell lysis buffer (#78501, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with protease inhibitors and phosphatase inhibitors (Roche, Basel, Switzerland). β-catenin antibody (1:5000, bs-0530R, Abcam, Cambridge, UK) was added to the cell lysate and incubated for 10 min at room temperature with rotation, followed by the addition of Dynabeads Protein A (10001D, Thermo Fisher Scientific, Waltham, MA, USA) with rotation for 1 h at 4℃ to precipitate the antigen-antibody complexes. After washing the beads twice with washing buffer, the precipitated complex was eluted, separated by SDS-PAGE, and detected by western blot with KLF15 antibody (1:500, ab2647; Abcam, Cambridge, UK). For the negative control (IP: IgG), normal rabbit IgG (same species and isotype as the primary antibody) was added to an identical amount of lysate and processed in parallel with Dynabeads Protein A under the same conditions. Whole cell lysates were also analyzed as input to confirm protein expression. Double immunofluorescence To confirm the colocalization of KLF15 and β-catenin in chondrocytes, fluorescent immunostaining was performed in chondrocytes from control mice (n = 5). Sections were incubated with 3% hydrogen peroxide (Wako Pure Chemical Corporation, Osaka, Japan) for 30 min. The sections were incubated overnight at 4℃ with anti-KLF15 antibody (1:500, ab2647; Abcam, Cambridge, UK) and anti-β-catenin antibody (1:5000, bs-0530R; Abcam, Cambridge, UK) as primary antibodies, and then incubated with the corresponding secondary antibodies (Alexa Fluor 488-conjugated goat anti-mouse, 1:500; A-11001, Alexa Fluor 568-conjugated rabbit anti-mouse, 1:500; A-11061, Thermo Fisher Scientific, Waltham, MA, USA) for 2 h at room temperature in the dark. For nuclear staining, 4′,6-diamidino-2-phenylindole (DAPI; Thermo Fisher Scientific, Waltham, MA, USA) was added and incubated at room temperature for 5 min. The cells were imaged using a confocal microscope. Cytoplasmic and nuclear protein extraction To compare β-catenin expression levels in cytoplasmic and nuclear fractions, western blot analysis was performed following subcellular fractionation. Primary chondrocytes were isolated from fetal costal cartilage of control and KLF15 knockout (KLF15 KO) mice. Cytoplasmic and nuclear proteins were extracted using homemade buffers (Buffer A and Buffer C). Buffer A consisted of 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, and 0.5 mM phenylmethylsulfonyl fluoride (PMSF). Buffer C consisted of 20 mM HEPES (pH 7.9), 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, and 1 mM PMSF. Protease and phosphatase inhibitors were added immediately before use. Briefly, chondrocytes were lysed in ice-cold Buffer A for 15 min. IGEPAL CA-630 (CAS No. 9002-93-1) was then added, and the lysates were centrifuged at 12,000 rpm for 30 s at 4°C. The resulting supernatants were collected as the cytoplasmic fractions. The remaining pellets were resuspended in ice-cold Buffer C, followed by centrifugation at 12,000 rpm for 5 min at 4°C to obtain the nuclear fractions. Western blot analysis Chondrocytes (n = 4) were lysed using the NucleoSpin RNA/Protein kit (Takara Bio, Tokyo, Japan), and the total protein concentration was quantified using the Bradford method and protein assay reagent (Bio-Rad). Anti-β-catenin antibody (1:5000, bs-0530R, Abcam, Cambridge, UK) was used as the primary antibody. Horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G antibody (IgG Ab, GE Healthcare, Little Chalfont, UK) was used as the secondary antibody, and signals were visualized using ECL Plus reagent (GE Healthcare) on a Chemilumino Analyzer LAS-3000 mini (FujiFilm, Tokyo, Japan). As internal controls, rabbit polyclonal anti-Histone H3 antibody (1:8000; 17168-1-AP, Proteintech) was used for the nuclear fraction, and mouse monoclonal anti-GAPDH antibody (1:50000; 60004-1-Ig, Proteintech, Chicago, IL, USA) was used for the cytoplasmic fraction, and these were used to correct the purity and expression levels of the fractions. Protein expression was determined by semi-quantification of digitally captured images using NIH ImageJ software ( http://imagej.nih.gov/ij/ ). Quantitative RT-PCR analysis Chondrocytes were cultured in 6-well plates for 24 h with or without stimulation by recombinant mouse Wnt3A protein (200 ng/mL, ab81484, Abcam, Cambridge, UK) and/or XAV-939 (200 ng/mL, S1180, Selleck Chemicals, Houston, TX, USA). Total RNA was extracted using QIAshredder and RNeasy Mini Kit (Qiagen, Valencia, California, USA). In detail, 1 µg of total RNA was reverse transcribed into first-strand cDNA using 1.25 µM oligo dT primer in 40 µL PCR buffer II containing 2.5 mM MgCl2, 0.5 mM dNTP mix, 0.5 U RNase inhibitor, and 1.25 U MuLV reverse transcriptase (PerkinElmer, Foster City, CA, USA) for 60 min at 42℃. Relative expression of β-catenin, Axin-like protein or conductin (Axin2, ADAMTS5), MMP13, SOX9, and the gene Col2A1 , which encodes the alpha chain of type II collagen, was quantified by SYBR Green real-time PCR using an ABI Prism 7500 system (Applied Biosystems, Foster City, CA, USA). The relative expression of the target genes was normalized to that of the GAPDH housekeeping gene using the comparative cycle threshold (Ct) value method. The difference in the mean Ct value of the target gene and the housekeeping gene is shown as ΔCt, and the difference between ΔCt and the Ct value of the calibration sample is shown as ΔΔCt. Log2(ΔΔCt) represented the relative value of gene expression. Primer sequences are listed in Supplementary Figure S1 . Statistical analyses Two-way analysis of variance (ANOVA) was used for statistical analysis, followed by Tukey’s post hoc test for multiple comparisons. Mann–Whitney U tests were used for comparisons between two groups. Statistical analyses were performed using EZR (Easy R), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). Results were expressed as means with 95% confidence intervals (CI). A p -value < 0.05 was considered statistically significant. Results KLF15 knockout mice are more susceptible to OA-related changes in vivo At 8 weeks postoperatively, KLF15 KO mice exhibited greater cartilage erosion and loss of Safranin O staining compared with control mice (Fig. 1 A). According to the OARSI cartilage OA histopathology scoring system, the mean total scores in both KLF15 KO and control mice were significantly higher at 4 and 8 weeks after DMM surgery compared with sham-operated mice (Fig. 1 B; KLF15 KO mice: p = 0.0086 and p = 0.0021, respectively; control mice: p = 0.0411 and p = 0.0021, respectively). The mean total score was significantly higher in KLF15 KO mice than in control mice at both 4 and 8 weeks postoperatively ( p = 0.0259 and p = 0.0259, respectively). KLF15 KO mice are more susceptible to changes in OA due to increased expression of β-catenin In KLF15 KO mice, β-catenin expression was increased compared to control mice (Fig. 2 A). The positive cell ratio of β-catenin was significantly increased in KLF15 KO mice compared with control mice at 4 and 8 weeks after surgery ( p = 0.0259 and p = 0.0259, respectively; Fig. 2 B). It was also significantly increased in both KLF15 KO and control mice at 4 and 8 weeks after DMM surgery compared with sham-operated mice (Fig. 2 B, p = 0.0086 and p = 0.0021, respectively, in KLF15 KO mice, and p = 0.0411 and p = 0.0021, respectively, in control mice). KLF15 KO mice exhibit increased catabolic factor expression in cartilage KLF15 KO mice showed higher MMP13 and ADAMTS5 expression compared with control mice (Fig. 3 A, C). In KLF15 KO mice, the positive cell ratio of MMP13 was significantly increased at 4 and 8 weeks after surgery, and the positive cell ratio of ADAMTS5 was significantly increased at 1, 4, and 8 weeks after surgery (Fig. 3 B, D; MMP13: p = 0.0303 and p = 0.0259, respectively; ADAMTS5: p = 0.0043, p = 0.0021, and p = 0.0021, respectively). Compared to sham mice, the positive cell ratio of MMP13 was significantly increased in KLF15 KO mice at 4 and 8 weeks after surgery and in control mice at 8 weeks after surgery (KLF15 KO: p = 0.0303 and p = 0.0021, respectively; control: p = 0.0043). The positive cell ratio of ADAMTS5 was significantly increased in KLF15 KO mice at 1, 4, and 8 weeks and was similarly increased in control mice at 8 weeks after DMM surgery compared with sham mice (KLF15 KO: p = 0.0269, p = 0.0001, and p < 0.0001, respectively; control: p = 0.0043). KLF15 KO mice exhibit decreased SOX9 expression, contributing to OA progression SOX9 expression was reduced in KLF15 KO mice compared with that in control mice (Fig. 3 E). The positive cell ratio of SOX9 was significantly decreased in KLF15 KO mice compared with control mice at all observation time points (Fig. 3 F; p = 0.0086, p = 0.0086, p = 0.0259, p = 0.0086, and p = 0.0151, respectively). The positive cell ratio of SOX9 was significantly decreased in both KLF15 KO and control mice compared to sham mice at 4 and 8 weeks after DMM surgery (KLF15 KO: p = 0.0014 and p < 0.0001, respectively; control: p = 0.0016 and p < 0.0001, respectively). KLF15 interacts with β-catenin in the nucleus of chondrocytes, while KLF15 deficiency activates the Wnt/β-catenin pathway Co-immunoprecipitation was performed in chondrocytes from control mice to examine whether KLF15 interacts directly with β-catenin. Chondrocyte cell lysates were immunoprecipitated with β-catenin, and KLF15 was detected by western blotting. A clear band of the expected size for KLF15 was detected, confirming the interaction between KLF15 and β-catenin (Fig. 4 A). Immunofluorescence staining revealed that KLF15 and β-catenin stained more intensely at the same position in the nucleus, confirming that KLF15 and β-catenin colocalize in chondrocyte nuclei (Fig. 4 B). Real-time RT-PCR analysis showed that β-catenin and Axin2 mRNA expression in chondrocytes derived from KLF15 KO mice was significantly higher than that in control mice (Fig. 4 C, p = 0.0003 and p = 0.0357, respectively). KLF15KO and control mouse chondrocytes were separated by cell fractionation, and the expression levels of β-catenin protein in the cytoplasm and nucleus were detected by western blotting. There was no significant difference in the expression level of β-catenin in the cytoplasm between KLF15KO and control mice (Fig. 4 D, 4 E: p = 0.7023). The expression level of β-catenin in the nucleus was significantly higher in KLF15KO mice than in control mice (Fig. 4 F, 4 G: p < 0.0001). Real-time RT-PCR of the Wnt/β-catenin pathway, catabolic factors, and anabolic factors following Wnt3A stimulation and XAV939 treatment in KLF15 KO mouse chondrocytes Real-time RT-PCR analysis showed that Wnt3A stimulation significantly increased the expression of β-catenin, Axin2, MMP13, and ADAMTS5 in both KLF15KO and control mice (β-catenin, p < 0.0001 and p < 0.0001, respectively; Axin2, p < 0.0001 and p < 0.0001, respectively; MMP13, p = 0.0027 and p = 0.0005, respectively; ADAMTS5, p < 0.0001 and p < 0.0001, respectively). Furthermore, the increase in expression of these four genes by Wnt3A stimulation was canceled by XAV939 treatment in both KLF15KO and control mice, and their expression was significantly decreased (β-catenin, p < 0.0001 and p < 0.0001, Axin2, p < 0.0001 and p < 0.0001; MMP13, p = 0.0045 and p = 0.0045, respectively; ADAMTS5, p < 0.0001 and p < 0.0001, respectively). Wnt3A stimulation significantly decreased the expression of SOX9 and Col2A1 in both KLF15KO and control mice (all p < 0.0001). Furthermore, the decrease in the expression of these two genes by Wnt3A stimulation was canceled by XAV939 administration in both KLF15KO and control mice, and their expression was significantly increased (SOX9, p < 0.0001 and p < 0.0001, respectively; Col2A1, p = 0.0003 and p < 0.0001, respectively). Wnt3A stimulation significantly increased the expression of β-catenin, Axin2, and ADAMTS5 in KLF15KO mice compared to control mice ( p < 0.0001, p < 0.0001, and p < 0.0001, respectively). Conversely, the expression of SOX9 and Col2A1 was significantly decreased ( p < 0.0001 and p = 0.0122, respectively). These findings were consistent with the in vivo results. Discussion This study presents the first evidence that KLF15 negatively regulates Wnt/β-catenin signaling in cartilage and that it may play an important role in OA progression. Specifically, KLF15 suppresses β-catenin activity and helps to maintain cartilage matrix homeostasis in both mouse models and fetal costal chondrocytes in vitro . Wnt ligand binding to Frizzled receptors and LRP5/6 inhibits β-catenin degradation, allowing it to accumulate in the cytoplasm and translocate into the nucleus, activating TCF/LEF-dependent transcription. 36 , 37 Excessive activation of the Wnt/β-catenin signaling pathway induces the expression of matrix-degrading enzymes, such as MMP13 and ADAMTS5, promoting OA pathology. 30 Experimental β-catenin overactivation in chondrocytes produces OA-like changes including osteophyte formation, cartilage thinning, and joint space narrowing. This suggests that β-catenin activation directly promotes cartilage destruction. 31 Indeed, the nuclear localization of β-catenin and the expression of its target genes are increased in the articular cartilage of patients with OA. 38 In non-cartilage tissues, KLF15 has been shown to inhibit Wnt/β-catenin signaling by binding to β-catenin and promoting its proteasomal degradation. 39 KLF15 induction has also been shown to suppress Wnt/β-catenin signaling by binding to active β-catenin and inhibiting its phosphorylation in renal interstitial cells. 40 Furthermore, KLF15 may directly suppress β-catenin transcriptional activity by physically binding to β-catenin and forming a protein complex. KLF15 deficiency enhanced β-catenin activity and increased expression of MMP13 and ADAMTS5 while reducing SOX9 and Col2A1, indicating a shift toward a catabolic state. 41 These changes were further intensified by Wnt3a stimulation and partially rescued by XAV939, a β-catenin inhibitor that stabilizes AXIN2 and promotes β-catenin degradation. Consistent with our findings, previous studies have shown that β-catenin overactivation leads to structural abnormalities, not only in articular cartilage but also in intervertebral disc tissue, further supporting the destructive potential of this pathway in cartilage structure. 42 XAV-939, a well-characterized small molecule inhibitor, stabilizes AXIN2 as a tankyrase inhibitor, thereby forming a degradation complex and promoting the phosphorylation-dependent degradation of β-catenin. 43 In a previous study, intra-articular injection of XAV939 in a DMM mouse model attenuated the severity of OA and demonstrated anti-catabolic effects in chondrocytes. 44 The results of this study indicate that KLF15 deficiency induces a catabolic environment via excessive activation of Wnt/β-catenin signaling, thereby promoting cartilage destruction. Furthermore, inhibition of the Wnt/β-catenin signaling pathway suppresses catabolic factor expression, indicating that OA-like changes associated with KLF15 deficiency occur via this pathway. In addition, reduced anabolic factor expression in response to KLF15 deficiency indicates that the ability of chondrocytes to maintain differentiation and synthesize the matrix was significantly impaired. This reduction was partially restored by XAV939 administration, revealing that abnormal activation of the Wnt/β-catenin pathway is also involved in the breakdown of the anabolic environment. Therefore, KLF15 may suppress OA progression by interacting with and negatively regulating β-catenin in the cell nucleus, thereby suppressing the expression of cartilage-degrading enzymes, and maintaining an anabolic state (Fig. 6 ). Limitations This study has some limitations. First, KLF15 was specifically knocked out in cartilage tissue, so the environment may be different from the real-life disease environment. This is because OA is a complex disease that progresses with degeneration of synovium, bone, and meniscus in addition to cartilage tissue. 45 , 46 Second, fetal costal chondrocytes were used in vitro , not knee articular cartilage. Ideally, knee chondrocytes from adult mice should have been used. However, we were unable to obtain the estimated number of knee chondrocytes required for this experiment. The findings of this study suggest that KLF15 is a potential therapeutic target for OA. If the Wnt/β-catenin pathway can be selectively suppressed by interventions that activate or restore KLF15 function, it may be possible to slow down or even prevent the destruction of articular cartilage and maintain cartilage differentiation. In addition, the development of small-molecule compounds that enhance the nuclear interaction between KLF15 and β-catenin and the restoration of KLF15 function by gene transfer should be considered as future approaches for treatment. However, because KLF15 is also involved in glucose metabolism and adipogenesis, its usefulness as a therapeutic target must be assessed in the context of its systemic effects. Declarations Ethics approval and consent to participants All animal experiments were approved by the Animal Experimentation Committee of Kobe University (Approval No. P230606) and conducted in accordance with institutional guidelines and the ARRIVE reporting standards. All efforts were made to minimize animal suffering and to reduce the number of animals used. Consent for publication Not applicable. Availability of data and materials The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request. Competing of interests The authors declare no conflicts of interest. Funding This study was funded by the Grant-in-Aid for Scientific Research (21K09278). Author’s contributions Akira Saitoh (Acquisition of the data, Analysis and interpretation of the data, Drafting of the article, Final approval of the article), Shinya Hayashi (Conception and design, Analysis and interpretation of the data, Drafting of the article, Obtaining of funding, Final approval of the article), Toshiki Kitamura (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Takuma Hayashi (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Kohe Motono (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Shotaro Araki (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Takuma Maeda (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Yoshihito Suda (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Kensuke Wada (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Kemmei Ikuta (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Masanori Tsubosaka (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Tomoyuki Kamenaga (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Yuichi Kuroda (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Naoki Nakano (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Tomoyuki Matsumoto (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Tetsuya Hosooka (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Wataru Ogawa (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Ryosuke Kuroda (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article). Acknowledgments We wish to thank Ms. Minako Nagata, Ms. Maya Yasuda, and Ms. Kyoko Tanaka for their expert technical assistance. This study was funded by the Grant-in-Aid for Scientific Research (21K09278). We would like to thank Editage (www.editage.com) for English language editing. References Hunter DJ, Bierma-Zeinstra S, Osteoarthritis. Lancet. 2019;393(10182):1745–59. 10.1016/S0140-6736(19)30417-9 . Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-analysis of sex differences in prevalence, incidence, and severity of osteoarthritis. Osteoarthritis Cartilage. 2005;13(9):769–81. 10.1016/j.joca.2005.04.014 . Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, et al. Osteoarthritis. Nat Rev Dis Primers. 2016;2:16072. 10.1038/nrdp.2016.72 . Glyn-Jones S, Palmer AJR, Agricola R, Price AJ, Vincent TL, Weinans H, et al. Osteoarthr Lancet. 2015;386(9991):376–87. 10.1016/S0140-6736(14)60802-3 . Loughead JM, Malhan K, Mitchell SY, Pinder IM, McCaskie AW, Deehan DJ, et al. Outcome following knee arthroplasty beyond 15 years. Knee. 2008;15(2):85–90. 10.1016/j.knee.2007.11.003 . Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73(7):1323–30. 10.1136/annrheumdis-2013-204763 . Yuce K, Ozkan AI. The Kruppel-like factor (KLF) family, diseases, and physiological events. Gene. 2024;895:148027. 10.1016/j.gene.2023.148027 . McConnell BB, Yang VW. Mammalian Krüppel-like factors in health and diseases. Physiol Rev. 2010;90(4):1337–81. 10.1152/physrev.00058.2009 . Pollak NM, Hoffman M, Goldberg IJ, Drosatos K. Krüppel-like factors: crippling and un-crippling metabolic pathways. JACC Basic Transl Sci. 2018;3(1):132–56. 10.1016/j.jacbts.2017.09.001 . Kawata M, Teramura T, Ordoukhanian P, Head SR, Natarajan P, Sundaresan A, et al. Krüppel-like factor-4 and Krüppel-like factor-2 regulate joint tissue cells and protect against tissue destruction and inflammation in osteoarthritis. Ann Rheum Dis. 2022;81(8):1179–88. 10.1136/annrheumdis-2021-221867 . Hu K, Sun Z, Deng L, Wang D, Fan J, Ma R, et al. KLF2 protects against osteoarthritis by repressing oxidative response through activation of Nrf2/ARE signaling. Oxid Med Cell Longev. 2019;2019:8564681. 10.1155/2019/8564681 . Li Y, Wang Y, Chen L, Liu W, Wang Y. KLF2 inhibits ferroptosis and improves mitochondrial dysfunction in chondrocytes via SIRT1/GPX4 signaling in osteoarthritis. Aging. 2021;13(8):11176–88. 10.18632/aging.202895 . Hu B, Sun X, Guo Z, Pan X, Wang X, Zhu L, et al. Krüppel-like factors 4 and 2 protect against osteoarthritis via transcriptional regulation in joint tissues. Bone Joint Res. 2021;10(1):39–51. 10.1302/2046-3758.101.BJR-2020-0192.R1 . Kawata M, McClatchy DB, Diedrich JK, Olmer M, Johnson KA, Yates JR, et al. Mocetinostat activates Krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis. JCI Insight. 2023;8(17):e170513. 10.1172/jci.insight.170513 . Yoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty AH, Matsuzaka T, et al. Adipose KLF15 controls lipid handling to adapt to nutrient availability. J Clin Invest. 2017;127(10):3561–74. 10.1172/JCI95341 . Pearson R, Fleetwood J, Eaton S, Crossley M, Bao S. Krüppel-like factors: a functional family of transcription factors with diverse roles in tissue homeostasis. Clin Sci (Lond). 2008;114(3):131–46. 10.1042/CS20070215 . Wang L, Lin W, Chen J. Krüppel-like factor 15: a potential therapeutic target for kidney disease. Int J Biol Sci. 2019;15(9):1955–61. 10.7150/ijbs.34838 . Mori T, Sakaue H, Iguchi H, Gomi H, Okada Y, Takashima Y, et al. Role of Krüppel-like factor 15 (KLF15) in transcriptional regulation of adipogenesis. J Biol Chem. 2005;280(13):12867–75. 10.1074/jbc.M410515200 . Haldar SM, Jeyaraj D, Anand P, Zhu H, Lu Y, Prosdocimo DA, et al. Kruppel-like factor 15 regulates skeletal muscle lipid flux and exercise adaptation. Proc Natl Acad Sci U S A. 2012;109(17):6739–44. 10.1073/pnas.1121060109 . Zhuo Q, Yang W, Chen J, Wang Y. Metabolic syndrome meets osteoarthritis. Nat Rev Rheumatol. 2012;8(12):729–37. 10.1038/nrrheum.2012.135 . Mei Z, Yilamu K, Ni W, Shen P, Pan N, Chen H, et al. Chondrocyte fatty acid oxidation drives osteoarthritis via SOX9 degradation and epigenetic regulation. Nat Commun. 2025;16(1):4892. 10.1038/s41467-025-60037-4 . Song Z, Lian X, Wang Y, Xiang Y, Li G. KLF15 regulates in vitro chondrogenic differentiation of human mesenchymal stem cells by targeting SOX9. Biochem Biophys Res Commun. 2017;493(2):1082–8. 10.1016/j.bbrc.2017.09.078 . Li Y, Zhao M, Xiao W. KLF15 regulates the expression of MMP-3 in human chondrocytes. J Interferon Cytokine Res. 2018;38(8):356–62. 10.1089/jir.2017.0135 . Ikuta K, Hayashi S, Kikuchi K, Fujita M, Anjiki K, Onoi Y, et al. Krüppel-like factor 15 deficiency exacerbates osteoarthritis through reduced expression of peroxisome proliferator-activated receptor gamma signaling in mice. Osteoarthritis Cartilage. 2024;32(1):28–40. 10.1016/j.joca.2023.08.009 . Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192–205. 10.1016/j.cell.2012.05.012 . Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3. 10.1038/s41392-021-00762-6 . Xue C, Chu Q, Shi Q, Zeng Y, Lu J, Li L. Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances. Signal Transduct Target Ther. 2025;10(1):106. 10.1038/s41392-025-02142-w . Lietman C, Wu B, Lechner S, Shinar A, Sehgal M, Rossomacha E, et al. Inhibition of Wnt/β-catenin signaling ameliorates osteoarthritis in a murine model of experimental osteoarthritis. JCI Insight. 2018;3(3):e96308. 10.1172/jci.insight.96308 . Li X, Han Y, Li G, Zhang Y, Wang J, Feng C. Role of Wnt signaling pathway in joint development and cartilage degeneration. Front Cell Dev Biol. 2023;11:1181619. 10.3389/fcell.2023.1181619 . Zhu M, Tang D, Wu Q, Hao S, Chen M, Xie C, et al. Activation of β-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult β-catenin conditional activation mice. J Bone Min Res. 2009;24(1):12–21. 10.1359/jbmr.080901 . Xia C, Wang P, Fang L, Ge Q, Zou Z, Dong R, et al. Activation of β-catenin in Col2-expressing chondrocytes leads to osteoarthritis-like defects in hip joint. J Cell Physiol. 2019;234(10):18535–43. 10.1002/jcp.28491 . Noack C, Iyer LM, Liaw NY, Schoger E, Khadjeh S, Wagner E, et al. KLF15–Wnt-dependent cardiac reprogramming up-regulates SHISA3 in the mammalian heart. J Am Coll Cardiol. 2019;74(14):1804–19. 10.1016/j.jacc.2019.07.076 . Hirata Y, Nomura K, Senga Y, Okada Y, Kobayashi K, Okamoto S, et al. Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis. JCI Insight. 2019;4(10):e124952. 10.1172/jci.insight.124952 . Ma HL, Blanchet TJ, Peluso D, Hopkins B, Morris EA, Glasson SS. Osteoarthritis severity is sex dependent in a surgical mouse model. Osteoarthritis Cartilage. 2007;15(6):695–700. 10.1016/j.joca.2006.11.005 . Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage. 2007;15(9):1061–9. 10.1016/j.joca.2007.03.006 . MacDonald BT, He X. Frizzled and LRP5/6 receptors for Wnt/β-catenin signaling. Cold Spring Harb Perspect Biol. 2012;4(12):a007880. 10.1101/cshperspect.a007880 . Ding Z, Lu W, Dai C, Huang W, Liu F, Shan W, et al. The CRD of Frizzled 7 exhibits chondroprotective effects in osteoarthritis via inhibition of the canonical Wnt3a/β-catenin signaling pathway. Int Immunopharmacol. 2020;82:106367. 10.1016/j.intimp.2020.106367 . Yuasa T, Otani T, Koike T, Iwamoto M, Enomoto-Iwamoto M. Wnt/β-catenin signaling stimulates matrix catabolic genes and activity in articular chondrocytes: its possible role in joint degeneration. Lab Invest. 2008;88(3):264–74. 10.1038/labinvest.3700747 . Noack C, Zafiriou MP, Schaeffer HJ, Renger A, Pavlova E, Dietz R, et al. Krüppel-like factor 15 regulates Wnt/β-catenin transcription and controls cardiac progenitor cell fate in the postnatal heart. EMBO Mol Med. 2012;4(9):992–1007. 10.1002/emmm.201101043 . Gu X, Mallipattu SK, Guo Y, Revelo MP, Pace J, Miller T, et al. Loss of Krüppel-like factor 15 in Foxd1 + stromal cells exacerbates kidney fibrosis. Kidney Int. 2017;92(5):1178–93. 10.1016/j.kint.2017.03.037 . Ning B, Wang P, Pei X, Kang Y, Song J, Wang D, et al. Dual function of β-catenin in articular cartilage growth and degeneration at different stages of postnatal cartilage development. Int Orthop. 2012;36(3):655–64. 10.1007/s00264-011-1315-6 . Wang M, Tang D, Shu B, Wang B, Jin H, Hao S, et al. Conditional activation of β-catenin signaling in mice leads to severe defects in intervertebral disc tissue. Arthritis Rheum. 2012;64(8):2611–23. 10.1002/art.34469 . Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461(7264):614–20. 10.1038/nature08356 . Lietman C, Wu B, Lechner S, Shinar A, Sehgal M, Rossomacha E, et al. Inhibition of Wnt/β-catenin signaling ameliorates osteoarthritis in a murine model of experimental osteoarthritis. JCI Insight. 2018;3(3):e96308. 10.1172/jci.insight.96308 . Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697–707. 10.1002/art.34453 . Loeser RF, Collins JA, Diekman BO. Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12(7):412–20. 10.1038/nrrheum.2016.65 . Additional Declarations No competing interests reported. Supplementary Files Supplementalfigure.docx Cite Share Download PDF Status: Under Review Version 1 posted Editorial decision: Revision requested 02 Feb, 2026 Reviews received at journal 31 Jan, 2026 Reviewers agreed at journal 21 Jan, 2026 Reviews received at journal 18 Jan, 2026 Reviewers agreed at journal 08 Jan, 2026 Reviewers invited by journal 05 Jan, 2026 Editor assigned by journal 25 Dec, 2025 Submission checks completed at journal 24 Dec, 2025 First submitted to journal 22 Dec, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8429330","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":569578652,"identity":"4dc6be92-cc70-408d-bfde-c3b3a65e96c0","order_by":0,"name":"Akira Saitoh","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Akira","middleName":"","lastName":"Saitoh","suffix":""},{"id":569578654,"identity":"9840aed0-e749-4e46-8d1b-ca99f1703268","order_by":1,"name":"Shinya Hayashi","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABEklEQVRIiWNgGAWjYDACCTB5gIcfzD7AkACTYCaoRbKBVC0MBgfQtOAE8rObn0n8+HNHxvja4YM3GM7Y5PEz8Bgw/KhhYDfHocXgzjEzyd62Zzxmt9OSLRhupBVLNvAYMPYcY2C2bMChRSLBTIK34TBQS46ZBMOHw4kb7r8xYOBtYGAGORWrw2akf5P88+cwj/Hs/G9gLfsPAG35i0cLw40cM2ketsM8BtI5bBIMN4C2AP3CjM8Wgxs5xdaybYd5JG6nGVsknEkrljjAVnBY5pgETr8AHbbx5ps/h+35Zyc/vPHhGDDEGpg3PnxTY5OMK8SAgEUCzkyA0kAnSSQb4NbC/AGrsB0eLaNgFIyCUTCyAAAIkFvK/j6ksQAAAABJRU5ErkJggg==","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":true,"prefix":"","firstName":"Shinya","middleName":"","lastName":"Hayashi","suffix":""},{"id":569578655,"identity":"8b8890ff-83e1-411d-b3ef-b20d9a52db85","order_by":2,"name":"Toshiki Kitamura","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Toshiki","middleName":"","lastName":"Kitamura","suffix":""},{"id":569578656,"identity":"dc7433ca-93aa-409e-b935-267fa23cb478","order_by":3,"name":"Takuma Hayashi","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Takuma","middleName":"","lastName":"Hayashi","suffix":""},{"id":569578657,"identity":"0f55a51b-4880-4a2d-ac1c-864da4b074a9","order_by":4,"name":"Kohei Motono","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Kohei","middleName":"","lastName":"Motono","suffix":""},{"id":569578659,"identity":"a388b72e-9011-403a-88bb-81baaec88cfc","order_by":5,"name":"Shotaro Araki","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Shotaro","middleName":"","lastName":"Araki","suffix":""},{"id":569578660,"identity":"c346fd4b-73dc-46da-ac2c-ba22857e7718","order_by":6,"name":"Takuma Maeda","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Takuma","middleName":"","lastName":"Maeda","suffix":""},{"id":569578662,"identity":"d0316676-e554-4d0c-8a5c-eb6c06990d94","order_by":7,"name":"Yoshihito Suda","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Yoshihito","middleName":"","lastName":"Suda","suffix":""},{"id":569578664,"identity":"3d5c3594-8ce0-40e7-b309-b29964ed21ed","order_by":8,"name":"Kensuke Wada","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Kensuke","middleName":"","lastName":"Wada","suffix":""},{"id":569578665,"identity":"109cbf89-b83c-4f00-9161-13ed55617552","order_by":9,"name":"Kemmei Ikuta","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Kemmei","middleName":"","lastName":"Ikuta","suffix":""},{"id":569578666,"identity":"b6f77974-7fc1-4c63-b232-31a7c0c1128b","order_by":10,"name":"Masanori Tsubosaka","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Masanori","middleName":"","lastName":"Tsubosaka","suffix":""},{"id":569578667,"identity":"3df2b7d2-f9e1-44de-87df-981819b28ce0","order_by":11,"name":"Tomoyuki Kamenaga","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Tomoyuki","middleName":"","lastName":"Kamenaga","suffix":""},{"id":569578668,"identity":"5d0b777e-a793-4d00-83f0-19bde348c2cf","order_by":12,"name":"Yuichi Kuroda","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Yuichi","middleName":"","lastName":"Kuroda","suffix":""},{"id":569578669,"identity":"220fd6a0-0871-456a-909b-908ba3f4526a","order_by":13,"name":"Naoki Nakano","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Naoki","middleName":"","lastName":"Nakano","suffix":""},{"id":569578670,"identity":"c1d16170-6736-4b50-8604-4374e327af1a","order_by":14,"name":"Tomoyuki Matsumoto","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Tomoyuki","middleName":"","lastName":"Matsumoto","suffix":""},{"id":569578671,"identity":"94b0381a-192b-4da7-b321-ba441084755f","order_by":15,"name":"Tetsuya Hosooka","email":"","orcid":"","institution":"University of Shizuoka","correspondingAuthor":false,"prefix":"","firstName":"Tetsuya","middleName":"","lastName":"Hosooka","suffix":""},{"id":569578672,"identity":"eaa4d3ae-6991-4d0e-9de8-ee7d12cb559b","order_by":16,"name":"Wataru Ogawa","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Wataru","middleName":"","lastName":"Ogawa","suffix":""},{"id":569578673,"identity":"89e38d4c-633c-4a57-8574-7e5e29d7605c","order_by":17,"name":"Ryosuke Kuroda","email":"","orcid":"","institution":"Kobe University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Ryosuke","middleName":"","lastName":"Kuroda","suffix":""}],"badges":[],"createdAt":"2025-12-23 02:38:27","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8429330/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8429330/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":99813362,"identity":"7841eda8-22ef-47ac-b3b9-4198c0af1563","added_by":"auto","created_at":"2026-01-08 14:38:56","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":2367670,"visible":true,"origin":"","legend":"","description":"","filename":"2025.12.23Manuscriptsaitoh.docx","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/4bd8f16f4ba1a07e5bc3a76e.docx"},{"id":99813537,"identity":"446587f1-dc41-4b41-a92c-f762c624aef0","added_by":"auto","created_at":"2026-01-08 14:39:14","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":19612,"visible":true,"origin":"","legend":"","description":"","filename":"461eab04392f425eae96dc8b81a205d0.json","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/73b24ab7d3c7a188cb9ad67e.json"},{"id":99813393,"identity":"7f043509-d9ff-4789-be5b-332d904db19f","added_by":"auto","created_at":"2026-01-08 14:39:01","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":22582,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementalfigure.docx","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/d1428f20a2027f1d1aa13ffc.docx"},{"id":99813700,"identity":"a093ee31-ea7d-4080-b0b5-a09fd02ed046","added_by":"auto","created_at":"2026-01-08 14:39:31","extension":"xml","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":132956,"visible":true,"origin":"","legend":"","description":"","filename":"461eab04392f425eae96dc8b81a205d01enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/33762937e7a0302cd7105324.xml"},{"id":99813792,"identity":"d7b27ddf-ed79-4258-92af-721d9fa00d57","added_by":"auto","created_at":"2026-01-08 14:39:51","extension":"jpeg","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1195828,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/6c668f455e64983fa07eacef.jpeg"},{"id":99813347,"identity":"cf6310f1-d48a-475b-bbff-6115ee1bef58","added_by":"auto","created_at":"2026-01-08 14:38:54","extension":"jpeg","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1239574,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/5d5c9970ace88f688867f08e.jpeg"},{"id":99813519,"identity":"2979007c-b71f-4972-8605-09266644df46","added_by":"auto","created_at":"2026-01-08 14:39:14","extension":"jpeg","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":395891,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage3.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/4b3e3590773e67f9af96c756.jpeg"},{"id":99813325,"identity":"0ea17e1f-3b5d-4b8d-8f2c-0ab307044ff2","added_by":"auto","created_at":"2026-01-08 14:38:50","extension":"jpeg","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":472177,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage4.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/6619b47f66fc1f3004ab5cec.jpeg"},{"id":99813348,"identity":"ec0ba6a1-fd48-450c-85bd-764b31f3bfde","added_by":"auto","created_at":"2026-01-08 14:38:54","extension":"png","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":76686,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage5.png","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/245097f6e5e012e499579bd1.png"},{"id":99813366,"identity":"d9db2cfc-fe4a-4a08-b722-fe10c0ae85ea","added_by":"auto","created_at":"2026-01-08 14:38:56","extension":"png","order_by":9,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":398745,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/f995790ec4ed1ed2d5c9a14a.png"},{"id":99813403,"identity":"a5c141fb-facf-4f67-9eee-bc1cf731376e","added_by":"auto","created_at":"2026-01-08 14:39:08","extension":"png","order_by":10,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":391877,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/54add895331275b597aa41e6.png"},{"id":99813238,"identity":"a9c9f038-e7ed-40f8-a5ab-b7bac6d37ba0","added_by":"auto","created_at":"2026-01-08 14:38:43","extension":"png","order_by":11,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":69810,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/f5ccd63b7045973fd90179da.png"},{"id":99813356,"identity":"fed8550c-a346-4931-8b22-d760aa6ce7e2","added_by":"auto","created_at":"2026-01-08 14:38:55","extension":"png","order_by":12,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":106985,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/76981e5f491011a78b30d6c8.png"},{"id":99813240,"identity":"ad295121-d7a7-4953-9df4-f018a5262cf6","added_by":"auto","created_at":"2026-01-08 14:38:43","extension":"png","order_by":13,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":23859,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage5.png","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/889954afbcedc5759f45eb92.png"},{"id":99813834,"identity":"54c41212-0286-47ff-b564-7bc9e7708ed5","added_by":"auto","created_at":"2026-01-08 14:39:52","extension":"xml","order_by":14,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":133046,"visible":true,"origin":"","legend":"","description":"","filename":"461eab04392f425eae96dc8b81a205d01structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/171a44f5bb1d50da811050ba.xml"},{"id":99813400,"identity":"95823344-ce33-4554-aa77-a7b4041b2b06","added_by":"auto","created_at":"2026-01-08 14:39:02","extension":"html","order_by":15,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":146184,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/cd7b873503508ad3bb019216.html"},{"id":99813707,"identity":"a34c2b89-8cb1-48e6-b7b4-8a6a1e92281b","added_by":"auto","created_at":"2026-01-08 14:39:32","extension":"jpeg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":331183,"visible":true,"origin":"","legend":"\u003cp\u003eKLF15 knockout mice exhibit more advanced OA.\u003c/p\u003e\n\u003cp\u003e(A) Knee tissue samples were collected postoperatively from the right tibia of KLF15 cKO and control mice at various time points after DMM and sham surgery. Sections were stained with Safranin O and fast green. Scale bar: 100 µm.\u003c/p\u003e\n\u003cp\u003e(B) OARSI scores of KLF15 cKO and control mice at various time points after DMM and sham surgery.\u003c/p\u003e\n\u003cp\u003eData are shown as box plots with whiskers. Each circle represents an individual mouse (n = 6 per group). The Friedman test followed by Wilcoxon signed-rank test was performed to compare the assessments at each time point, while the Mann–Whitney U test was performed for group comparisons at each assessment. *\u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05 indicates a significant difference between the indicated groups.\u003c/p\u003e\n\u003cp\u003eAbbreviations: p.o.: Postoperative, cKO: Conditional knockout, KLF15: Krüppel-like factor 15, OA: Osteoarthritis, OARSI: Osteoarthritis Research Society International, DMM: Destabilization of medial meniscus surgery.\u003c/p\u003e","description":"","filename":"1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/cc90721eb2e2f07f23515b5d.jpeg"},{"id":99813689,"identity":"17d985b6-1b94-4159-9f5c-cf3b143d86df","added_by":"auto","created_at":"2026-01-08 14:39:30","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":503845,"visible":true,"origin":"","legend":"\u003cp\u003eβ-catenin expression is increased in KLF15 knockout mice.\u003c/p\u003e\n\u003cp\u003e(A) Immunohistochemical staining with anti-β-catenin antibody. Scale bar: 100 µm.\u003c/p\u003e\n\u003cp\u003e(B) Quantitative data of β-catenin-positive cells in each group.\u003c/p\u003e\n\u003cp\u003eData are shown as box plots with whiskers. Each circle represents an individual mouse (n = 6 per group). The Friedman test followed by Wilcoxon signed-rank test was performed to compare the assessments at each time point, while the Mann–Whitney U test was performed for group comparisons at each assessment. *\u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05 indicates a significant difference between the indicated groups.\u003c/p\u003e\n\u003cp\u003eAbbreviations: p.o.: Postoperative, KO: Knockout, KLF15: Krüppel-like factor 15.\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/ee20b86fdd3f98ef36237615.png"},{"id":99813353,"identity":"6285d412-8585-4375-9cd0-0093b8d918f6","added_by":"auto","created_at":"2026-01-08 14:38:54","extension":"jpeg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":197445,"visible":true,"origin":"","legend":"\u003cp\u003eKLF15 deficiency increases catabolic factor expression and decreases anabolic factor expression in chondrocytes.\u003c/p\u003e\n\u003cp\u003e(A, B, C) Immunohistochemical staining with antibodies against MMP13, ADAMTS5, and SOX9. Scale bar: 100 µm.\u003c/p\u003e\n\u003cp\u003e(D, E, F) Quantitative data of MMP13-, ADAMTS5-, and SOX9-positive cells in each group. Data are shown as box plots with whiskers. Each circle represents an individual mouse (n = 6 per group). The Friedman test followed by Wilcoxon signed-rank test was performed to compare the assessments at each time point, while the Mann–Whitney U test was performed for comparison between groups at each assessment. *\u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05 indicates a significant difference between the indicated groups.\u003c/p\u003e\n\u003cp\u003eAbbreviations: p.o.: Post-surgery, KO: Knockout, KLF15: Krüppel-like factor 15, MMP13: Matrix metalloprotease-13, ADAMTS: A disintegrin-like metalloprotease with thrombospondin motifs, SOX9: SRY-box transcription factor 9.\u003c/p\u003e","description":"","filename":"3.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/57ace2049d3eed08d842b13d.jpeg"},{"id":99813620,"identity":"0f7552a6-e4ba-4f84-9527-7a148ea73dac","added_by":"auto","created_at":"2026-01-08 14:39:29","extension":"jpeg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":395891,"visible":true,"origin":"","legend":"\u003cp\u003eKLF15 interacts with β-catenin and colocalizes in the nucleus.\u003c/p\u003e\n\u003cp\u003e(A) Co-immunoprecipitation using chondrocytes from control mice. Chondrocyte lysates were subjected to immunoprecipitation with anti–β-catenin antibody (lane 2, IP: β-catenin) or control IgG (lane 3, IP: IgG), followed by immunoblotting with anti-KLF15 antibody. Lane 1 (Input) represents 5% of the total cell lysate before immunoprecipitation and serves as a positive control for KLF15 expression, whereas the IgG lane serves as a negative control to confirm the specificity of the KLF15–β-catenin interaction.\u003c/p\u003e\n\u003cp\u003e(B) Immunofluorescence staining of KLF15 and β-catenin in chondrocytes. KLF15 was stained with Alexa Fluor 488 (green), β-catenin with Alexa Fluor 594 (red), and nuclei were counterstained with DAPI (blue). Co-localization is indicated by yellow circles in merged images. Scale bar: 100 µm.\u003c/p\u003e\n\u003cp\u003e(C) Real-time RT-PCR analyses for the mRNA expression of β-catenin and Axin2 in chondrocytes from KLF15 KO and control mice.\u003c/p\u003e\n\u003cp\u003e(D, F) Western blotting for β-catenin protein expression separately in the cytoplasm and nucleus. GAPDH and Histone H3 were used for normalization in the cytoplasm and nucleus, respectively.\u003c/p\u003e\n\u003cp\u003e(E, G) Relative band intensity values are calculated as the ratio of protein of interest to that of GAPDH or Histone H3.\u003c/p\u003e\n\u003cp\u003eData are presented as box plots with whiskers. Each circle represents an individual trial (RT-PCR: n = 6; western blotting results: n = 4). The Friedman test followed by the Wilcoxon signed-rank test was performed to compare the ratings for each time point, while the Mann–Whitney U test was performed to compare the groups in each assessment. *\u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05 indicates a significant differences between the indicated groups.\u003c/p\u003e\n\u003cp\u003eAbbreviations: KLF15: Krüppel-like factor 15, DAPI: 4′,6-diamidino-2-phenylindole, RT-PCR: Reverse-transcription polymerase chain reaction, KO: Knockout, GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.\u003c/p\u003e","description":"","filename":"4.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/c9ac6a01a1e30d5627fcba29.jpeg"},{"id":99813323,"identity":"05cbc292-cd2d-48bb-b22f-bb1dc0b6c9f4","added_by":"auto","created_at":"2026-01-08 14:38:50","extension":"jpeg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":472177,"visible":true,"origin":"","legend":"\u003cp\u003eEnhancement of Wnt/β-catenin signaling, catabolic factor amplification, and anabolic factor suppression induced by Wnt3A stimulation were canceled by treatment with a Wnt/β-catenin signaling inhibitor in chondrocytes from KLF15KO and control mice.\u003c/p\u003e\n\u003cp\u003e(A, B, C, D, E, F) Real-time RT-PCR analyses for the mRNA expression of β-catenin, Axin2, MMP13, ADAMTS5, Sox9, and Col2A1 in chondrocytes from KLF15 KO and control mice treated with or without Wnt3A (200 ng/mL) or Wnt/β-catenin signaling inhibitor (XAV-939, 200 ng/mL). Chondrocytes from control mice not treated with either Wnt3A or Wnt/β-catenin signaling inhibitor were used as controls.\u003c/p\u003e\n\u003cp\u003eData are presented as box plots with whiskers. Each circle represents an individual trial (RT-PCR: n = 6). The Friedman test followed by the Wilcoxon signed-rank test was performed to compare the ratings for each time point, while the Mann–Whitney U test was performed to compare the groups in each assessment. *\u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05 indicates a significant differences between the indicated groups.\u003c/p\u003e\n\u003cp\u003eAbbreviations: KLF15: Krüppel-like factor 15, RT-PCR: Reverse-transcription polymerase chain reaction, KO: Knockout, MMP13: Matrix metalloprotease-13, ADAMTS: A disintegrin-like metalloprotease with thrombospondin motifs, SOX9: SRY-box transcription factor 9, Col2A1: Collagen type 2 alpha 1.\u003c/p\u003e","description":"","filename":"5.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/d66e91ee8809bf4096c03b93.jpeg"},{"id":99813239,"identity":"c4393ab0-9b1f-46fa-bac6-4e3c778c267b","added_by":"auto","created_at":"2026-01-08 14:38:43","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":76686,"visible":true,"origin":"","legend":"\u003cp\u003eKLF15 may suppress OA progression by interacting with β-catenin in the cell nucleus, negatively regulating β-catenin, suppressing the expression of cartilage-degrading enzymes, and maintaining anabolic factors.\u003c/p\u003e\n\u003cp\u003eAbbreviations: KLF15: Krüppel-like factor 15, OA: Osteoarthritis.\u003c/p\u003e","description":"","filename":"6.png","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/f1c60aefd3e9731580761840.png"},{"id":99816234,"identity":"a2ac0dc8-eb9a-4727-9419-0e73f7f2e68b","added_by":"auto","created_at":"2026-01-08 14:46:18","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":3006499,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/24b61645-603e-4bf6-9b6f-014cbcf5e39b.pdf"},{"id":99813559,"identity":"a1bcd1e5-249c-4572-9390-9143a73c8ea7","added_by":"auto","created_at":"2026-01-08 14:39:17","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":22582,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementalfigure.docx","url":"https://assets-eu.researchsquare.com/files/rs-8429330/v1/dcb65b18cf3c426ccc2aab97.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Deficiency of Krüppel-like factor 15 activates β-catenin and is involved in the development of osteoarthritis","fulltext":[{"header":"Background","content":"\u003cp\u003eOsteoarthritis (OA) is a common joint disease that develops due to aging and lifestyle habits, which significantly reduces quality of life.\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e,\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e The pathology of OA progresses as a series of complex changes in the entire joint structure, accompanied by degeneration of articular cartilage, synovitis, bone sclerosis, and osteophyte formation. To date, no effective disease-modifying treatment has been established to treat OA.\u003csup\u003e3.4\u003c/sup\u003e Artificial joint replacement surgery has delivered good long-term results.\u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e However, the efficacy of conservative treatments such as analgesics, hyaluronic acid injections, and rehabilitation is limited in their efficacy.\u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e Therefore, elucidating the mechanisms underlying OA progression and identifying new therapeutic targets is necessary.\u003c/p\u003e \u003cp\u003eKr\u0026uuml;ppel-like factors (KLFs) are a family of transcription factors with C2H2-type zinc fingers that are involved in a wide range of biological processes.\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e Currently, 17 members of the KLF family have been identified, each with different tissue specificities and functions.\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e Recently, the involvement of KLFs in OA has attracted attention. In particular, KLF2 and KLF4, which are involved in the maintenance of chondrocyte homeostasis, are known to be associated with OA pathology.\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e KLF2 inhibits oxidative stress and ferroptosis and protects mitochondrial function in chondrocytes, thereby suppressing OA progression. Specifically, KLF2 inhibits the oxidative stress response by activating Nrf2/ARE signaling.\u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e It improves ferroptosis and mitochondrial dysfunction via the SIRT1/GPX4 pathway, thereby alleviating OA pathology.\u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e KLF4 promotes chondrocyte differentiation and expression of extracellular matrix (ECM) components, and is considered an important transcription factor in cartilage repair regulation. Furthermore, KLF4 has a protective function in OA by regulating the inflammatory response of synovial cells and chondrocytes and suppressing tissue destruction.\u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e,\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eKLF15 is a metabolism-related transcription factor that functions as a key regulator of metabolic homeostasis in various tissues, specifically in lipid metabolism and energy homeostasis.\u003csup\u003e\u003cspan additionalcitationids=\"CR16 CR17\" citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e In skeletal muscle, KLF15 cooperates with peroxisome proliferator-activated receptor delta (PPARδ) to regulate lipid flux and maintain mitochondrial function, contributing to exercise response and muscle function adaptation.\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e However, the possibility that KLF15 may also be involved in the pathology of OA has recently attracted attention. Disruption of lipid metabolism is considered a new pathological factor involved in the disturbance of cartilage homeostasis and OA progression.\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e Abnormal fatty acid oxidation impairs cartilage homeostasis through SRY-box transcription factor 9 (SOX9) degradation and epigenetic regulation.\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e Such metabolic abnormalities promote cartilage degeneration. Therefore, KLF15 may function as a metabolic regulator even within chondrocytes. KLF15 directly induces SOX9 expression during chondrogenic differentiation of human mesenchymal stem cells (hMSCs) and promotes cartilage differentiation.\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e Additionally, KLF15 expression is significantly reduced in chondrocytes derived from patients with OA compared with healthy individuals.\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e Furthermore, KLF15 plays a role in suppressing the inflammatory response and progression of matrix degradation by suppressing matrix metalloproteinase-13 (MMP-13) transcription in response to tumor necrosis factor-alpha (TNFα) stimulation.\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e Our previous study reported that KLF15 deficiency reduces peroxisome proliferator-activated receptor gamma (PPARγ) expression, which promotes chondrocyte apoptosis, resulting in the worsening of OA pathology.\u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e Thus, KLF15 is a multifaceted transcription factor that contributes to the metabolic regulation, differentiation control, and suppression of inflammatory responses in cartilage. Specifically, its role in homeostasis is extremely important. However, the role of KLF15 in cartilage homeostasis and the progression of OA pathology has not yet been fully elucidated, and further research is required.\u003c/p\u003e \u003cp\u003eThe Wnt/β-catenin signaling pathway is a highly conserved and fundamental signaling cascade that plays pivotal roles in several biological processes.\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e Canonical Wnt signaling through β-catenin is activated by Wnt ligand binding to the cell surface Frizzled receptor and co-receptor low-density lipoprotein receptor-related protein (LRP) 5/6. In the absence of Wnt ligands, cytoplasmic β-catenin is targeted for proteasomal degradation via a degradation complex, which phosphorylates β-catenin and marks it for ubiquitination. Upon Wnt activation, this degradation machinery is inactivated and β-catenin accumulates in the cytoplasm before translocating to the nucleus. There, Wnt/β-catenin activates the transcription of various target genes involved in cell proliferation, differentiation, and matrix remodeling.\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e The Wnt/β-catenin pathway is essential for proper cartilage tissue development and maintenance under physiological conditions. Its dysregulation has been suggested to be deeply involved in OA pathology. Evidence suggests that abnormal or persistent activation of this pathway promotes the expression of degradative enzymes, such as MMP13 and disintegrin-like metalloprotease with thrombospondin motifs 5 (ADAMTS5), which are central mediators of ECM degradation in OA cartilage.\u003csup\u003e\u003cspan additionalcitationids=\"CR28\" citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e These enzymes degrade collagen type II alpha 1 (Col2A1) and aggrecan, resulting in the structural destruction of articular cartilage. In particular, overexpression of β-catenin has been reported to be involved in the progression of OA.\u003csup\u003e30,31\u003c/sup\u003e Interestingly, recent studies suggest that transcription factors, such as KLF15, which regulate metabolic and signaling pathways in other tissues, such as the heart and kidney, may interact with Wnt/β-catenin signaling.\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e,\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e These findings suggest that KLF15 may also affect cartilage integrity by regulating the expression of β-catenin in chondrocytes.\u003c/p\u003e \u003cp\u003eInformation regarding the crosstalk between KLF15 and β-catenin in OA pathology is currently scarce. Understanding the precise nature of the involvement of KLF15 in the Wnt/β-catenin pathway may help to identify novel transcriptional regulatory mechanisms in OA and aid in identifying future therapeutic targets. In this study, we aimed to evaluate how the interaction between KLF15 and β-catenin regulates OA progression using a KLF15-deficient mouse model.\u003c/p\u003e"},{"header":"Materials and methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eGeneration of inducible cartilage-specific KLF15 knockout mice\u003c/h2\u003e \u003cp\u003eMice were maintained under a 12-h light/dark cycle with free access to food and water. Klf15\u003csup\u003efl/fl\u003c/sup\u003e mice were generated as described previously.\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e Col2-CreERT2 mice were obtained from Jackson Laboratories (Bar Harbor, Maine, USA). Klf15\u003csup\u003efl/fl\u003c/sup\u003e mice were crossed with Col2-CreERT2 mice to generate inducible KLF15 knockout mice (Klf15\u003csup\u003efl/fl\u003c/sup\u003e Cre mice). Genotyping was performed on tail biopsy samples by polymerase chain reaction (PCR) using a DNA extraction kit (Qiagen, Valencia, California, USA). Klf15\u003csup\u003efl/fl\u003c/sup\u003e littermates negative for Col2-CreERT2 were used as wild-type controls. To induce gene deletion, 6-week-old Klf15\u003csup\u003efl/fl\u003c/sup\u003e Cre mice and control mice were intraperitoneally injected with 4-hydroxytamoxifen (40 mg/kg) for 5 consecutive days. In this study, only male mice were used because they develop more severe OA than females.\u003csup\u003e\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e All mice were backcrossed to the C57BL/6 background for more than six generations. Each experimental group included at least six mice.\u003c/p\u003e \u003cp\u003e \u003cb\u003eIn vivo\u003c/b\u003e \u003cb\u003eOA mouse model\u003c/b\u003e\u003c/p\u003e \u003cp\u003e All animal procedures were conducted in strict accordance with the National Institutes of Health guidelines for the care and use of laboratory animals (Bethesda, MD, USA). The Animal Research Committee of Kobe University approved the protocol (approval number: P230606). Ten-week-old male Klf15\u003csup\u003efl/fl\u003c/sup\u003e Cre and control mice were used. All surgical procedures were performed on the right knee joint under combined anesthesia (medetomidine, 0.375 mg/kg; midazolam, 2.0 mg/kg; butorphanol, 2.5 mg/kg). OA was induced by destabilization of the medial meniscus (DMM) via medial meniscotibial ligament.\u003csup\u003e\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u003c/sup\u003e Sham operations involved exposure without ligament transection. Mice were allowed to bear weight after recovery. Mice were euthanized for histological evaluation at 1 day, 1 week, 4 weeks, and 8 weeks post-operation or at 8 weeks post-sham. Six mice were analyzed per group (total n\u0026thinsp;=\u0026thinsp;60; KLF15 KO Sham, KLF15 KO DMM, Control Sham, Control DMM).\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eHistological evaluation of cartilage degeneration\u003c/h3\u003e\n\u003cp\u003eKnee joints were fixed in 10% neutral-buffered formalin for 24 h, decalcified with 4% ethylenediaminetetraacetic acid for 7 days, and embedded in paraffin. Coronal sections were cut at 80 \u0026micro;m intervals and stained with Safranin O and Fast Green. OA severity was evaluated using the Osteoarthritis Research Society International (OARSI) cartilage histopathology scoring system.\u003c/p\u003e\n\u003ch3\u003eImmunohistochemistry\u003c/h3\u003e\n\u003cp\u003eDeparaffinized sections were digested for 10 min with proteinase (Dako, Glostrup, Denmark) and treated with 3% hydrogen peroxide (Wako Pure Chemical Industries, Osaka, Japan) to block endogenous peroxidase activity. Sections were incubated overnight at 4\u0026deg;C with the following primary antibodies: anti-β-catenin (1:5000, bs-0530R, Abcam, Cambridge, UK), anti-ADAMTS5 (1:50, GTX100332, GeneTex, Irvine, CA, USA), anti-MMP13 (1:50, GTX100665, GeneTex), and anti-SOX9 (1:200, ab185230, Abcam, Cambridge, UK). Secondary antibody incubation was performed using peroxidase-labeled antirabbit immunoglobulin (Histofine Simple Stain MAX PO; Nichirei Biosciences, Tokyo, Japan) at 22\u0026thinsp;\u0026plusmn;\u0026thinsp;2℃ for 30 min, followed by staining with 3,3'-diaminobenzidine (DAB; Histofine Simple Stain DAB kit; Nichirei Biosciences, Tokyo, Japan). One coronal section at the center of the most severe OA lesion of each tibial plateau was analyzed. The number of positively stained cells in both superficial and deep zones of cartilage was counted in three high-power fields by three blinded observers. The mean percentage of positive cells to total cells was calculated for each marker per group (n\u0026thinsp;=\u0026thinsp;6). Cells above the tidemark were considered positive.\u003c/p\u003e\n\u003ch3\u003eIsolation of mouse cartilage and chondrocytes\u003c/h3\u003e\n\u003cp\u003eCartilage tissues were isolated from fetal rib cages. Klf15\u003csup\u003efl/fl\u003c/sup\u003e Cre mice were mated, and pregnant female mice were intraperitoneally injected with tamoxifen at 12.5 and 13.5 days post coitum (dpc). Fetuses were harvested from these mice by Caesarean section at 18.5 dpc. Genotyping was performed on tail biopsy samples by PCR using a DNA extraction kit (Qiagen, Valencia, California, USA). Primary chondrocytes were isolated from cartilage by digestion with 3 mg/mL collagenase D (Roche, Basel, Switzerland) in Dulbecco\u0026rsquo;s Modified Eagle\u0026rsquo;s Medium (DMEM; D5546, Sigma-Aldrich, St. Louis, MO, USA) at 37℃ under 5% CO₂ for 45 min. The digestion was repeated after transferring the cartilage pieces to a new dish. The resulting cells were cultured overnight in a 1:5 mix of culture medium (DMEM supplemented with 2 mM glutamine, 50 U/mL penicillin, 0.05 mg/mL streptomycin) and digestion solution. Non-adherent cells were removed, and adherent cells were further cultured with 10% fetal bovine serum (FBS; 50 mL per 500 mL DMEM) for 5\u0026ndash;6 days until confluence. First-passage cells were used in all experiments.\u003c/p\u003e\n\u003ch3\u003eCo-immunoprecipitation\u003c/h3\u003e\n\u003cp\u003ePrimary cultured chondrocytes from control fetal costal cartilage were used. Cells were lysed in M-PER cell lysis buffer (#78501, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with protease inhibitors and phosphatase inhibitors (Roche, Basel, Switzerland). β-catenin antibody (1:5000, bs-0530R, Abcam, Cambridge, UK) was added to the cell lysate and incubated for 10 min at room temperature with rotation, followed by the addition of Dynabeads Protein A (10001D, Thermo Fisher Scientific, Waltham, MA, USA) with rotation for 1 h at 4℃ to precipitate the antigen-antibody complexes. After washing the beads twice with washing buffer, the precipitated complex was eluted, separated by SDS-PAGE, and detected by western blot with KLF15 antibody (1:500, ab2647; Abcam, Cambridge, UK). For the negative control (IP: IgG), normal rabbit IgG (same species and isotype as the primary antibody) was added to an identical amount of lysate and processed in parallel with Dynabeads Protein A under the same conditions. Whole cell lysates were also analyzed as input to confirm protein expression.\u003c/p\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eDouble immunofluorescence\u003c/h2\u003e \u003cp\u003eTo confirm the colocalization of KLF15 and β-catenin in chondrocytes, fluorescent immunostaining was performed in chondrocytes from control mice (n\u0026thinsp;=\u0026thinsp;5). Sections were incubated with 3% hydrogen peroxide (Wako Pure Chemical Corporation, Osaka, Japan) for 30 min. The sections were incubated overnight at 4℃ with anti-KLF15 antibody (1:500, ab2647; Abcam, Cambridge, UK) and anti-β-catenin antibody (1:5000, bs-0530R; Abcam, Cambridge, UK) as primary antibodies, and then incubated with the corresponding secondary antibodies (Alexa Fluor 488-conjugated goat anti-mouse, 1:500; A-11001, Alexa Fluor 568-conjugated rabbit anti-mouse, 1:500; A-11061, Thermo Fisher Scientific, Waltham, MA, USA) for 2 h at room temperature in the dark. For nuclear staining, 4\u0026prime;,6-diamidino-2-phenylindole (DAPI; Thermo Fisher Scientific, Waltham, MA, USA) was added and incubated at room temperature for 5 min. The cells were imaged using a confocal microscope.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eCytoplasmic and nuclear protein extraction\u003c/h3\u003e\n\u003cp\u003eTo compare β-catenin expression levels in cytoplasmic and nuclear fractions, western blot analysis was performed following subcellular fractionation. Primary chondrocytes were isolated from fetal costal cartilage of control and KLF15 knockout (KLF15 KO) mice. Cytoplasmic and nuclear proteins were extracted using homemade buffers (Buffer A and Buffer C). Buffer A consisted of 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, and 0.5 mM phenylmethylsulfonyl fluoride (PMSF). Buffer C consisted of 20 mM HEPES (pH 7.9), 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, and 1 mM PMSF. Protease and phosphatase inhibitors were added immediately before use. Briefly, chondrocytes were lysed in ice-cold Buffer A for 15 min. IGEPAL CA-630 (CAS No. 9002-93-1) was then added, and the lysates were centrifuged at 12,000 rpm for 30 s at 4\u0026deg;C. The resulting supernatants were collected as the cytoplasmic fractions. The remaining pellets were resuspended in ice-cold Buffer C, followed by centrifugation at 12,000 rpm for 5 min at 4\u0026deg;C to obtain the nuclear fractions.\u003c/p\u003e\n\u003ch3\u003eWestern blot analysis\u003c/h3\u003e\n\u003cp\u003eChondrocytes (n\u0026thinsp;=\u0026thinsp;4) were lysed using the NucleoSpin RNA/Protein kit (Takara Bio, Tokyo, Japan), and the total protein concentration was quantified using the Bradford method and protein assay reagent (Bio-Rad). Anti-β-catenin antibody (1:5000, bs-0530R, Abcam, Cambridge, UK) was used as the primary antibody. Horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G antibody (IgG Ab, GE Healthcare, Little Chalfont, UK) was used as the secondary antibody, and signals were visualized using ECL Plus reagent (GE Healthcare) on a Chemilumino Analyzer LAS-3000 mini (FujiFilm, Tokyo, Japan). As internal controls, rabbit polyclonal anti-Histone H3 antibody (1:8000; 17168-1-AP, Proteintech) was used for the nuclear fraction, and mouse monoclonal anti-GAPDH antibody (1:50000; 60004-1-Ig, Proteintech, Chicago, IL, USA) was used for the cytoplasmic fraction, and these were used to correct the purity and expression levels of the fractions. Protein expression was determined by semi-quantification of digitally captured images using NIH ImageJ software (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://imagej.nih.gov/ij/\u003c/span\u003e\u003cspan address=\"http://imagej.nih.gov/ij/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e).\u003c/p\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eQuantitative RT-PCR analysis\u003c/h2\u003e \u003cp\u003eChondrocytes were cultured in 6-well plates for 24 h with or without stimulation by recombinant mouse Wnt3A protein (200 ng/mL, ab81484, Abcam, Cambridge, UK) and/or XAV-939 (200 ng/mL, S1180, Selleck Chemicals, Houston, TX, USA). Total RNA was extracted using QIAshredder and RNeasy Mini Kit (Qiagen, Valencia, California, USA). In detail, 1 \u0026micro;g of total RNA was reverse transcribed into first-strand cDNA using 1.25 \u0026micro;M oligo dT primer in 40 \u0026micro;L PCR buffer II containing 2.5 mM MgCl2, 0.5 mM dNTP mix, 0.5 U RNase inhibitor, and 1.25 U MuLV reverse transcriptase (PerkinElmer, Foster City, CA, USA) for 60 min at 42℃. Relative expression of β-catenin, Axin-like protein or conductin (Axin2, ADAMTS5), MMP13, SOX9, and the gene \u003cem\u003eCol2A1\u003c/em\u003e, which encodes the alpha chain of type II collagen, was quantified by SYBR Green real-time PCR using an ABI Prism 7500 system (Applied Biosystems, Foster City, CA, USA). The relative expression of the target genes was normalized to that of the GAPDH housekeeping gene using the comparative cycle threshold (Ct) value method. The difference in the mean Ct value of the target gene and the housekeeping gene is shown as ΔCt, and the difference between ΔCt and the Ct value of the calibration sample is shown as ΔΔCt. Log2(ΔΔCt) represented the relative value of gene expression. Primer sequences are listed in Supplementary Figure \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analyses\u003c/h2\u003e \u003cp\u003eTwo-way analysis of variance (ANOVA) was used for statistical analysis, followed by Tukey\u0026rsquo;s post hoc test for multiple comparisons. Mann\u0026ndash;Whitney U tests were used for comparisons between two groups. Statistical analyses were performed using EZR (Easy R), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). Results were expressed as means with 95% confidence intervals (CI). A \u003cem\u003ep\u003c/em\u003e-value\u0026thinsp;\u0026lt;\u0026thinsp;0.05 was considered statistically significant.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003e \u003cb\u003eKLF15 knockout mice are more susceptible to OA-related changes\u003c/b\u003e \u003cb\u003ein vivo\u003c/b\u003e\u003c/p\u003e \u003cp\u003eAt 8 weeks postoperatively, KLF15 KO mice exhibited greater cartilage erosion and loss of Safranin O staining compared with control mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA). According to the OARSI cartilage OA histopathology scoring system, the mean total scores in both KLF15 KO and control mice were significantly higher at 4 and 8 weeks after DMM surgery compared with sham-operated mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB; KLF15 KO mice: \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0086 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0021, respectively; control mice: \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0411 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0021, respectively). The mean total score was significantly higher in KLF15 KO mice than in control mice at both 4 and 8 weeks postoperatively (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0259 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0259, respectively).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003eKLF15 KO mice are more susceptible to changes in OA due to increased expression of β-catenin\u003c/b\u003e \u003c/p\u003e \u003cp\u003eIn KLF15 KO mice, β-catenin expression was increased compared to control mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA). The positive cell ratio of β-catenin was significantly increased in KLF15 KO mice compared with control mice at 4 and 8 weeks after surgery (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0259 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0259, respectively; Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB). It was also significantly increased in both KLF15 KO and control mice at 4 and 8 weeks after DMM surgery compared with sham-operated mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB, p\u0026thinsp;=\u0026thinsp;0.0086 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0021, respectively, in KLF15 KO mice, and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0411 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0021, respectively, in control mice).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eKLF15 KO mice exhibit increased catabolic factor expression in cartilage\u003c/h2\u003e \u003cp\u003eKLF15 KO mice showed higher MMP13 and ADAMTS5 expression compared with control mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA, C). In KLF15 KO mice, the positive cell ratio of MMP13 was significantly increased at 4 and 8 weeks after surgery, and the positive cell ratio of ADAMTS5 was significantly increased at 1, 4, and 8 weeks after surgery (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB, D; MMP13: \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0303 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0259, respectively; ADAMTS5: \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0043, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0021, and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0021, respectively). Compared to sham mice, the positive cell ratio of MMP13 was significantly increased in KLF15 KO mice at 4 and 8 weeks after surgery and in control mice at 8 weeks after surgery (KLF15 KO: \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0303 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0021, respectively; control: \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0043). The positive cell ratio of ADAMTS5 was significantly increased in KLF15 KO mice at 1, 4, and 8 weeks and was similarly increased in control mice at 8 weeks after DMM surgery compared with sham mice (KLF15 KO: \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0269, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0001, and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001, respectively; control: \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0043).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eKLF15 KO mice exhibit decreased SOX9 expression, contributing to OA progression\u003c/h2\u003e \u003cp\u003eSOX9 expression was reduced in KLF15 KO mice compared with that in control mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eE). The positive cell ratio of SOX9 was significantly decreased in KLF15 KO mice compared with control mice at all observation time points (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eF; \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0086, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0086, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0259, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0086, and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0151, respectively). The positive cell ratio of SOX9 was significantly decreased in both KLF15 KO and control mice compared to sham mice at 4 and 8 weeks after DMM surgery (KLF15 KO: \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0014 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001, respectively; control: \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0016 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001, respectively).\u003c/p\u003e \u003cp\u003e \u003cb\u003eKLF15 interacts with β-catenin in the nucleus of chondrocytes, while KLF15 deficiency activates the Wnt/β-catenin pathway\u003c/b\u003e \u003c/p\u003e \u003cp\u003eCo-immunoprecipitation was performed in chondrocytes from control mice to examine whether KLF15 interacts directly with β-catenin. Chondrocyte cell lysates were immunoprecipitated with β-catenin, and KLF15 was detected by western blotting. A clear band of the expected size for KLF15 was detected, confirming the interaction between KLF15 and β-catenin (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA). Immunofluorescence staining revealed that KLF15 and β-catenin stained more intensely at the same position in the nucleus, confirming that KLF15 and β-catenin colocalize in chondrocyte nuclei (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eReal-time RT-PCR analysis showed that β-catenin and Axin2 mRNA expression in chondrocytes derived from KLF15 KO mice was significantly higher than that in control mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC, p\u0026thinsp;=\u0026thinsp;0.0003 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0357, respectively). KLF15KO and control mouse chondrocytes were separated by cell fractionation, and the expression levels of β-catenin protein in the cytoplasm and nucleus were detected by western blotting. There was no significant difference in the expression level of β-catenin in the cytoplasm between KLF15KO and control mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eD, \u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eE: \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.7023). The expression level of β-catenin in the nucleus was significantly higher in KLF15KO mice than in control mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eF, \u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eG: \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001).\u003c/p\u003e \u003cp\u003e \u003cb\u003eReal-time RT-PCR of the Wnt/β-catenin pathway, catabolic factors, and anabolic factors following Wnt3A stimulation and XAV939 treatment in KLF15 KO mouse chondrocytes\u003c/b\u003e \u003c/p\u003e \u003cp\u003eReal-time RT-PCR analysis showed that Wnt3A stimulation significantly increased the expression of β-catenin, Axin2, MMP13, and ADAMTS5 in both KLF15KO and control mice (β-catenin, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001, respectively; Axin2, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001, respectively; MMP13, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0027 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0005, respectively; ADAMTS5, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001, respectively). Furthermore, the increase in expression of these four genes by Wnt3A stimulation was canceled by XAV939 treatment in both KLF15KO and control mice, and their expression was significantly decreased (β-catenin, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001, Axin2, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001; MMP13, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0045 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0045, respectively; ADAMTS5, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001, respectively). Wnt3A stimulation significantly decreased the expression of SOX9 and Col2A1 in both KLF15KO and control mice (all \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001). Furthermore, the decrease in the expression of these two genes by Wnt3A stimulation was canceled by XAV939 administration in both KLF15KO and control mice, and their expression was significantly increased (SOX9, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001, respectively; Col2A1, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0003 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001, respectively). Wnt3A stimulation significantly increased the expression of β-catenin, Axin2, and ADAMTS5 in KLF15KO mice compared to control mice (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001, \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001, and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001, respectively). Conversely, the expression of SOX9 and Col2A1 was significantly decreased (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.0001 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.0122, respectively). These findings were consistent with the \u003cem\u003ein vivo\u003c/em\u003e results.\u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis study presents the first evidence that KLF15 negatively regulates Wnt/β-catenin signaling in cartilage and that it may play an important role in OA progression. Specifically, KLF15 suppresses β-catenin activity and helps to maintain cartilage matrix homeostasis in both mouse models and fetal costal chondrocytes \u003cem\u003ein vitro\u003c/em\u003e.\u003c/p\u003e \u003cp\u003eWnt ligand binding to Frizzled receptors and LRP5/6 inhibits β-catenin degradation, allowing it to accumulate in the cytoplasm and translocate into the nucleus, activating TCF/LEF-dependent transcription.\u003csup\u003e\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e,\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e Excessive activation of the Wnt/β-catenin signaling pathway induces the expression of matrix-degrading enzymes, such as MMP13 and ADAMTS5, promoting OA pathology.\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e Experimental β-catenin overactivation in chondrocytes produces OA-like changes including osteophyte formation, cartilage thinning, and joint space narrowing. This suggests that β-catenin activation directly promotes cartilage destruction.\u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eIndeed, the nuclear localization of β-catenin and the expression of its target genes are increased in the articular cartilage of patients with OA.\u003csup\u003e38\u003c/sup\u003e In non-cartilage tissues, KLF15 has been shown to inhibit Wnt/β-catenin signaling by binding to β-catenin and promoting its proteasomal degradation.\u003csup\u003e\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eKLF15 induction has also been shown to suppress Wnt/β-catenin signaling by binding to active β-catenin and inhibiting its phosphorylation in renal interstitial cells.\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e Furthermore, KLF15 may directly suppress β-catenin transcriptional activity by physically binding to β-catenin and forming a protein complex.\u003c/p\u003e \u003cp\u003eKLF15 deficiency enhanced β-catenin activity and increased expression of MMP13 and ADAMTS5 while reducing SOX9 and Col2A1, indicating a shift toward a catabolic state.\u003csup\u003e\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e\u003c/sup\u003e These changes were further intensified by Wnt3a stimulation and partially rescued by XAV939, a β-catenin inhibitor that stabilizes AXIN2 and promotes β-catenin degradation. Consistent with our findings, previous studies have shown that β-catenin overactivation leads to structural abnormalities, not only in articular cartilage but also in intervertebral disc tissue, further supporting the destructive potential of this pathway in cartilage structure.\u003csup\u003e\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u003c/sup\u003e XAV-939, a well-characterized small molecule inhibitor, stabilizes AXIN2 as a tankyrase inhibitor, thereby forming a degradation complex and promoting the phosphorylation-dependent degradation of β-catenin.\u003csup\u003e\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e\u003c/sup\u003e In a previous study, intra-articular injection of XAV939 in a DMM mouse model attenuated the severity of OA and demonstrated anti-catabolic effects in chondrocytes.\u003csup\u003e\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eThe results of this study indicate that KLF15 deficiency induces a catabolic environment via excessive activation of Wnt/β-catenin signaling, thereby promoting cartilage destruction. Furthermore, inhibition of the Wnt/β-catenin signaling pathway suppresses catabolic factor expression, indicating that OA-like changes associated with KLF15 deficiency occur via this pathway.\u003c/p\u003e \u003cp\u003eIn addition, reduced anabolic factor expression in response to KLF15 deficiency indicates that the ability of chondrocytes to maintain differentiation and synthesize the matrix was significantly impaired. This reduction was partially restored by XAV939 administration, revealing that abnormal activation of the Wnt/β-catenin pathway is also involved in the breakdown of the anabolic environment. Therefore, KLF15 may suppress OA progression by interacting with and negatively regulating β-catenin in the cell nucleus, thereby suppressing the expression of cartilage-degrading enzymes, and maintaining an anabolic state (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003eLimitations\u003c/h2\u003e \u003cp\u003eThis study has some limitations. First, KLF15 was specifically knocked out in cartilage tissue, so the environment may be different from the real-life disease environment. This is because OA is a complex disease that progresses with degeneration of synovium, bone, and meniscus in addition to cartilage tissue.\u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e,\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e Second, fetal costal chondrocytes were used \u003cem\u003ein vitro\u003c/em\u003e, not knee articular cartilage. Ideally, knee chondrocytes from adult mice should have been used. However, we were unable to obtain the estimated number of knee chondrocytes required for this experiment.\u003c/p\u003e \u003cp\u003eThe findings of this study suggest that KLF15 is a potential therapeutic target for OA. If the Wnt/β-catenin pathway can be selectively suppressed by interventions that activate or restore KLF15 function, it may be possible to slow down or even prevent the destruction of articular cartilage and maintain cartilage differentiation. In addition, the development of small-molecule compounds that enhance the nuclear interaction between KLF15 and β-catenin and the restoration of KLF15 function by gene transfer should be considered as future approaches for treatment. However, because KLF15 is also involved in glucose metabolism and adipogenesis, its usefulness as a therapeutic target must be assessed in the context of its systemic effects.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participants\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll animal experiments were approved by the Animal Experimentation Committee of Kobe University (Approval No. P230606) and conducted in accordance with institutional guidelines and the ARRIVE reporting standards. All efforts were made to minimize animal suffering and to reduce the number of animals used.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting of interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare no conflicts of interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study was funded by the Grant-in-Aid for Scientific Research (21K09278).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor\u0026rsquo;s contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAkira Saitoh (Acquisition of the data, Analysis and interpretation of the data, Drafting of the article, Final approval of the article), Shinya Hayashi (Conception and design, Analysis and interpretation of the data, Drafting of the article, Obtaining of funding, Final approval of the article), Toshiki Kitamura (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Takuma Hayashi (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Kohe Motono (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Shotaro Araki (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Takuma Maeda (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Yoshihito Suda (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Kensuke Wada (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Kemmei Ikuta (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Masanori Tsubosaka (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Tomoyuki Kamenaga (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Yuichi Kuroda (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Naoki Nakano (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Tomoyuki Matsumoto (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Tetsuya Hosooka (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Wataru Ogawa (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article), Ryosuke Kuroda (Analysis and interpretation of the data, Critical revision of the article for important intellectual content, Final approval of the article).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgments\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe wish to thank Ms. Minako Nagata, Ms. Maya Yasuda, and Ms. Kyoko Tanaka for their expert technical assistance. This study was funded by the Grant-in-Aid for Scientific Research (21K09278). We would like to thank Editage (www.editage.com) for English language editing.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eHunter DJ, Bierma-Zeinstra S, Osteoarthritis. Lancet. 2019;393(10182):1745\u0026ndash;59. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S0140-6736(19)30417-9\u003c/span\u003e\u003cspan address=\"10.1016/S0140-6736(19)30417-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSrikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-analysis of sex differences in prevalence, incidence, and severity of osteoarthritis. Osteoarthritis Cartilage. 2005;13(9):769\u0026ndash;81. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.joca.2005.04.014\u003c/span\u003e\u003cspan address=\"10.1016/j.joca.2005.04.014\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMartel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, et al. Osteoarthritis. Nat Rev Dis Primers. 2016;2:16072. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nrdp.2016.72\u003c/span\u003e\u003cspan address=\"10.1038/nrdp.2016.72\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGlyn-Jones S, Palmer AJR, Agricola R, Price AJ, Vincent TL, Weinans H, et al. Osteoarthr Lancet. 2015;386(9991):376\u0026ndash;87. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S0140-6736(14)60802-3\u003c/span\u003e\u003cspan address=\"10.1016/S0140-6736(14)60802-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLoughead JM, Malhan K, Mitchell SY, Pinder IM, McCaskie AW, Deehan DJ, et al. Outcome following knee arthroplasty beyond 15 years. Knee. 2008;15(2):85\u0026ndash;90. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.knee.2007.11.003\u003c/span\u003e\u003cspan address=\"10.1016/j.knee.2007.11.003\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73(7):1323\u0026ndash;30. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1136/annrheumdis-2013-204763\u003c/span\u003e\u003cspan address=\"10.1136/annrheumdis-2013-204763\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYuce K, Ozkan AI. The Kruppel-like factor (KLF) family, diseases, and physiological events. Gene. 2024;895:148027. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.gene.2023.148027\u003c/span\u003e\u003cspan address=\"10.1016/j.gene.2023.148027\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcConnell BB, Yang VW. Mammalian Kr\u0026uuml;ppel-like factors in health and diseases. Physiol Rev. 2010;90(4):1337\u0026ndash;81. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1152/physrev.00058.2009\u003c/span\u003e\u003cspan address=\"10.1152/physrev.00058.2009\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePollak NM, Hoffman M, Goldberg IJ, Drosatos K. Kr\u0026uuml;ppel-like factors: crippling and un-crippling metabolic pathways. JACC Basic Transl Sci. 2018;3(1):132\u0026ndash;56. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jacbts.2017.09.001\u003c/span\u003e\u003cspan address=\"10.1016/j.jacbts.2017.09.001\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKawata M, Teramura T, Ordoukhanian P, Head SR, Natarajan P, Sundaresan A, et al. Kr\u0026uuml;ppel-like factor-4 and Kr\u0026uuml;ppel-like factor-2 regulate joint tissue cells and protect against tissue destruction and inflammation in osteoarthritis. Ann Rheum Dis. 2022;81(8):1179\u0026ndash;88. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1136/annrheumdis-2021-221867\u003c/span\u003e\u003cspan address=\"10.1136/annrheumdis-2021-221867\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHu K, Sun Z, Deng L, Wang D, Fan J, Ma R, et al. KLF2 protects against osteoarthritis by repressing oxidative response through activation of Nrf2/ARE signaling. Oxid Med Cell Longev. 2019;2019:8564681. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1155/2019/8564681\u003c/span\u003e\u003cspan address=\"10.1155/2019/8564681\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi Y, Wang Y, Chen L, Liu W, Wang Y. KLF2 inhibits ferroptosis and improves mitochondrial dysfunction in chondrocytes via SIRT1/GPX4 signaling in osteoarthritis. Aging. 2021;13(8):11176\u0026ndash;88. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.18632/aging.202895\u003c/span\u003e\u003cspan address=\"10.18632/aging.202895\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHu B, Sun X, Guo Z, Pan X, Wang X, Zhu L, et al. Kr\u0026uuml;ppel-like factors 4 and 2 protect against osteoarthritis via transcriptional regulation in joint tissues. Bone Joint Res. 2021;10(1):39\u0026ndash;51. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1302/2046-3758.101.BJR-2020-0192.R1\u003c/span\u003e\u003cspan address=\"10.1302/2046-3758.101.BJR-2020-0192.R1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKawata M, McClatchy DB, Diedrich JK, Olmer M, Johnson KA, Yates JR, et al. Mocetinostat activates Kr\u0026uuml;ppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis. JCI Insight. 2023;8(17):e170513. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1172/jci.insight.170513\u003c/span\u003e\u003cspan address=\"10.1172/jci.insight.170513\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty AH, Matsuzaka T, et al. Adipose KLF15 controls lipid handling to adapt to nutrient availability. J Clin Invest. 2017;127(10):3561\u0026ndash;74. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1172/JCI95341\u003c/span\u003e\u003cspan address=\"10.1172/JCI95341\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePearson R, Fleetwood J, Eaton S, Crossley M, Bao S. Kr\u0026uuml;ppel-like factors: a functional family of transcription factors with diverse roles in tissue homeostasis. Clin Sci (Lond). 2008;114(3):131\u0026ndash;46. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1042/CS20070215\u003c/span\u003e\u003cspan address=\"10.1042/CS20070215\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang L, Lin W, Chen J. Kr\u0026uuml;ppel-like factor 15: a potential therapeutic target for kidney disease. Int J Biol Sci. 2019;15(9):1955\u0026ndash;61. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.7150/ijbs.34838\u003c/span\u003e\u003cspan address=\"10.7150/ijbs.34838\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMori T, Sakaue H, Iguchi H, Gomi H, Okada Y, Takashima Y, et al. Role of Kr\u0026uuml;ppel-like factor 15 (KLF15) in transcriptional regulation of adipogenesis. J Biol Chem. 2005;280(13):12867\u0026ndash;75. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1074/jbc.M410515200\u003c/span\u003e\u003cspan address=\"10.1074/jbc.M410515200\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHaldar SM, Jeyaraj D, Anand P, Zhu H, Lu Y, Prosdocimo DA, et al. Kruppel-like factor 15 regulates skeletal muscle lipid flux and exercise adaptation. Proc Natl Acad Sci U S A. 2012;109(17):6739\u0026ndash;44. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1073/pnas.1121060109\u003c/span\u003e\u003cspan address=\"10.1073/pnas.1121060109\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhuo Q, Yang W, Chen J, Wang Y. Metabolic syndrome meets osteoarthritis. Nat Rev Rheumatol. 2012;8(12):729\u0026ndash;37. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nrrheum.2012.135\u003c/span\u003e\u003cspan address=\"10.1038/nrrheum.2012.135\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMei Z, Yilamu K, Ni W, Shen P, Pan N, Chen H, et al. Chondrocyte fatty acid oxidation drives osteoarthritis via SOX9 degradation and epigenetic regulation. Nat Commun. 2025;16(1):4892. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41467-025-60037-4\u003c/span\u003e\u003cspan address=\"10.1038/s41467-025-60037-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSong Z, Lian X, Wang Y, Xiang Y, Li G. KLF15 regulates in vitro chondrogenic differentiation of human mesenchymal stem cells by targeting SOX9. Biochem Biophys Res Commun. 2017;493(2):1082\u0026ndash;8. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.bbrc.2017.09.078\u003c/span\u003e\u003cspan address=\"10.1016/j.bbrc.2017.09.078\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi Y, Zhao M, Xiao W. KLF15 regulates the expression of MMP-3 in human chondrocytes. J Interferon Cytokine Res. 2018;38(8):356\u0026ndash;62. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1089/jir.2017.0135\u003c/span\u003e\u003cspan address=\"10.1089/jir.2017.0135\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIkuta K, Hayashi S, Kikuchi K, Fujita M, Anjiki K, Onoi Y, et al. Kr\u0026uuml;ppel-like factor 15 deficiency exacerbates osteoarthritis through reduced expression of peroxisome proliferator-activated receptor gamma signaling in mice. Osteoarthritis Cartilage. 2024;32(1):28\u0026ndash;40. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.joca.2023.08.009\u003c/span\u003e\u003cspan address=\"10.1016/j.joca.2023.08.009\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192\u0026ndash;205. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.cell.2012.05.012\u003c/span\u003e\u003cspan address=\"10.1016/j.cell.2012.05.012\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41392-021-00762-6\u003c/span\u003e\u003cspan address=\"10.1038/s41392-021-00762-6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXue C, Chu Q, Shi Q, Zeng Y, Lu J, Li L. Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances. Signal Transduct Target Ther. 2025;10(1):106. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41392-025-02142-w\u003c/span\u003e\u003cspan address=\"10.1038/s41392-025-02142-w\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLietman C, Wu B, Lechner S, Shinar A, Sehgal M, Rossomacha E, et al. Inhibition of Wnt/β-catenin signaling ameliorates osteoarthritis in a murine model of experimental osteoarthritis. JCI Insight. 2018;3(3):e96308. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1172/jci.insight.96308\u003c/span\u003e\u003cspan address=\"10.1172/jci.insight.96308\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi X, Han Y, Li G, Zhang Y, Wang J, Feng C. Role of Wnt signaling pathway in joint development and cartilage degeneration. Front Cell Dev Biol. 2023;11:1181619. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fcell.2023.1181619\u003c/span\u003e\u003cspan address=\"10.3389/fcell.2023.1181619\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhu M, Tang D, Wu Q, Hao S, Chen M, Xie C, et al. Activation of β-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult β-catenin conditional activation mice. J Bone Min Res. 2009;24(1):12\u0026ndash;21. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1359/jbmr.080901\u003c/span\u003e\u003cspan address=\"10.1359/jbmr.080901\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXia C, Wang P, Fang L, Ge Q, Zou Z, Dong R, et al. Activation of β-catenin in Col2-expressing chondrocytes leads to osteoarthritis-like defects in hip joint. J Cell Physiol. 2019;234(10):18535\u0026ndash;43. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/jcp.28491\u003c/span\u003e\u003cspan address=\"10.1002/jcp.28491\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNoack C, Iyer LM, Liaw NY, Schoger E, Khadjeh S, Wagner E, et al. KLF15\u0026ndash;Wnt-dependent cardiac reprogramming up-regulates SHISA3 in the mammalian heart. J Am Coll Cardiol. 2019;74(14):1804\u0026ndash;19. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jacc.2019.07.076\u003c/span\u003e\u003cspan address=\"10.1016/j.jacc.2019.07.076\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHirata Y, Nomura K, Senga Y, Okada Y, Kobayashi K, Okamoto S, et al. Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis. JCI Insight. 2019;4(10):e124952. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1172/jci.insight.124952\u003c/span\u003e\u003cspan address=\"10.1172/jci.insight.124952\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMa HL, Blanchet TJ, Peluso D, Hopkins B, Morris EA, Glasson SS. Osteoarthritis severity is sex dependent in a surgical mouse model. Osteoarthritis Cartilage. 2007;15(6):695\u0026ndash;700. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.joca.2006.11.005\u003c/span\u003e\u003cspan address=\"10.1016/j.joca.2006.11.005\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGlasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage. 2007;15(9):1061\u0026ndash;9. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.joca.2007.03.006\u003c/span\u003e\u003cspan address=\"10.1016/j.joca.2007.03.006\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMacDonald BT, He X. Frizzled and LRP5/6 receptors for Wnt/β-catenin signaling. Cold Spring Harb Perspect Biol. 2012;4(12):a007880. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1101/cshperspect.a007880\u003c/span\u003e\u003cspan address=\"10.1101/cshperspect.a007880\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDing Z, Lu W, Dai C, Huang W, Liu F, Shan W, et al. The CRD of Frizzled 7 exhibits chondroprotective effects in osteoarthritis via inhibition of the canonical Wnt3a/β-catenin signaling pathway. Int Immunopharmacol. 2020;82:106367. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.intimp.2020.106367\u003c/span\u003e\u003cspan address=\"10.1016/j.intimp.2020.106367\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYuasa T, Otani T, Koike T, Iwamoto M, Enomoto-Iwamoto M. Wnt/β-catenin signaling stimulates matrix catabolic genes and activity in articular chondrocytes: its possible role in joint degeneration. Lab Invest. 2008;88(3):264\u0026ndash;74. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/labinvest.3700747\u003c/span\u003e\u003cspan address=\"10.1038/labinvest.3700747\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNoack C, Zafiriou MP, Schaeffer HJ, Renger A, Pavlova E, Dietz R, et al. Kr\u0026uuml;ppel-like factor 15 regulates Wnt/β-catenin transcription and controls cardiac progenitor cell fate in the postnatal heart. EMBO Mol Med. 2012;4(9):992\u0026ndash;1007. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/emmm.201101043\u003c/span\u003e\u003cspan address=\"10.1002/emmm.201101043\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGu X, Mallipattu SK, Guo Y, Revelo MP, Pace J, Miller T, et al. Loss of Kr\u0026uuml;ppel-like factor 15 in Foxd1\u0026thinsp;+\u0026thinsp;stromal cells exacerbates kidney fibrosis. Kidney Int. 2017;92(5):1178\u0026ndash;93. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.kint.2017.03.037\u003c/span\u003e\u003cspan address=\"10.1016/j.kint.2017.03.037\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNing B, Wang P, Pei X, Kang Y, Song J, Wang D, et al. Dual function of β-catenin in articular cartilage growth and degeneration at different stages of postnatal cartilage development. Int Orthop. 2012;36(3):655\u0026ndash;64. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00264-011-1315-6\u003c/span\u003e\u003cspan address=\"10.1007/s00264-011-1315-6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang M, Tang D, Shu B, Wang B, Jin H, Hao S, et al. Conditional activation of β-catenin signaling in mice leads to severe defects in intervertebral disc tissue. Arthritis Rheum. 2012;64(8):2611\u0026ndash;23. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/art.34469\u003c/span\u003e\u003cspan address=\"10.1002/art.34469\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461(7264):614\u0026ndash;20. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nature08356\u003c/span\u003e\u003cspan address=\"10.1038/nature08356\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLietman C, Wu B, Lechner S, Shinar A, Sehgal M, Rossomacha E, et al. Inhibition of Wnt/β-catenin signaling ameliorates osteoarthritis in a murine model of experimental osteoarthritis. JCI Insight. 2018;3(3):e96308. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1172/jci.insight.96308\u003c/span\u003e\u003cspan address=\"10.1172/jci.insight.96308\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLoeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697\u0026ndash;707. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/art.34453\u003c/span\u003e\u003cspan address=\"10.1002/art.34453\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLoeser RF, Collins JA, Diekman BO. Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12(7):412\u0026ndash;20. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nrrheum.2016.65\u003c/span\u003e\u003cspan address=\"10.1038/nrrheum.2016.65\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"arthritis-research-and-therapy","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"arrt","sideBox":"Learn more about [Arthritis Research \u0026 Therapy](http://arthritis-research.biomedcentral.com/)","snPcode":"13075","submissionUrl":"https://submission.nature.com/new-submission/13075/3","title":"Arthritis Research \u0026 Therapy","twitterHandle":"@ArthritisRes","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Krüppel-like factor 15, Wnt/β-catenin pathway, β-catenin, osteoarthritis, destabilization of medial meniscal surgery, Wnt3A, matrix metalloprotease 13, disintegrin-like metalloprotease with thrombospondin motifs 5, SRY-box transcription factor 9","lastPublishedDoi":"10.21203/rs.3.rs-8429330/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8429330/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eKr\u0026uuml;ppel-like factor 15 is a metabolism-related transcription factor that has been implicated in the regulation of the Wnt/β-catenin signaling pathway. This study aimed to elucidate its function in cartilage, particularly its interaction with β-catenin, using inducible cartilage-specific knockout mice. Kr\u0026uuml;ppel-like factor 15 knockout mice and control mice underwent destabilization of medial meniscal surgery to induce osteoarthritis. Histological analysis and immunohistochemistry were carried out, along with \u003cem\u003ein vitro\u003c/em\u003e co-immunoprecipitation, double immunofluorescence, and subcellular fractionation. The effects of Wnt3A stimulation and treatment with Wnt/β-catenin inhibitors were evaluated. KO mice showed significantly more cartilage degeneration at eight weeks after surgery when compared with control mice. Knockout mice also showed elevated Osteoarthritis Research Society International scores and increased expression of β-catenin, matrix metalloprotease 13, and a disintegrin-like metalloprotease with thrombospondin motifs 5, along with decreased expression of SRY-box transcription factor 9. Kr\u0026uuml;ppel-like factor 15 was seen to physically interact and colocalize with β-catenin in chondrocyte nuclei. Its deficiency promoted Wnt/β-catenin pathway activation and nuclear β-catenin accumulation. Wnt3A stimulation amplified catabolic gene expression and suppressed anabolic factor expression. However, administration of a Wnt/β-catenin signaling inhibitor canceled out these effects. This study indicates that Kr\u0026uuml;ppel-like factor 15 interacts with β-catenin and functions as a negative regulator of Wnt/β-catenin signaling in cartilage, maintaining matrix homeostasis, and suppressing osteoarthritis progression. Deficiency of Kr\u0026uuml;ppel-like factor 15 promotes catabolism and inhibits anabolism mediated by β-catenin in cartilage. These findings suggest that Kr\u0026uuml;ppel-like factor 15 may be a potential therapeutic target for osteoarthritis, either by restoring its function or enhancing its interaction with β-catenin.\u003c/p\u003e","manuscriptTitle":"Deficiency of Krüppel-like factor 15 activates β-catenin and is involved in the development of osteoarthritis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-01-08 14:03:49","doi":"10.21203/rs.3.rs-8429330/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2026-02-02T07:51:40+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-01-31T05:07:23+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"318817943568066125518335080077008651434","date":"2026-01-21T13:47:32+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-01-19T01:12:32+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"248661344237693092692924179303611350670","date":"2026-01-08T12:56:37+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2026-01-05T11:52:16+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-12-26T00:35:45+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-12-24T05:57:06+00:00","index":"","fulltext":""},{"type":"submitted","content":"Arthritis Research \u0026 Therapy","date":"2025-12-23T02:29:36+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"arthritis-research-and-therapy","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"arrt","sideBox":"Learn more about [Arthritis Research \u0026 Therapy](http://arthritis-research.biomedcentral.com/)","snPcode":"13075","submissionUrl":"https://submission.nature.com/new-submission/13075/3","title":"Arthritis Research \u0026 Therapy","twitterHandle":"@ArthritisRes","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"24487cd9-e29e-4fd8-a655-378de332652b","owner":[],"postedDate":"January 8th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2026-04-28T07:53:34+00:00","versionOfRecord":[],"versionCreatedAt":"2026-01-08 14:03:49","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8429330","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8429330","identity":"rs-8429330","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}